US20020115665A1 - Methods of and compounds for inhibiting calpains - Google Patents
Methods of and compounds for inhibiting calpains Download PDFInfo
- Publication number
- US20020115665A1 US20020115665A1 US09/847,872 US84787201A US2002115665A1 US 20020115665 A1 US20020115665 A1 US 20020115665A1 US 84787201 A US84787201 A US 84787201A US 2002115665 A1 US2002115665 A1 US 2002115665A1
- Authority
- US
- United States
- Prior art keywords
- amino
- methyl
- thiazolyl
- calpain
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 150000001875 compounds Chemical class 0.000 title claims abstract description 57
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 8
- 108010032088 Calpain Proteins 0.000 claims abstract description 80
- 102000007590 Calpain Human genes 0.000 claims abstract description 80
- 239000004030 hiv protease inhibitor Substances 0.000 claims abstract description 55
- 229940122440 HIV protease inhibitor Drugs 0.000 claims abstract description 37
- 230000001404 mediated effect Effects 0.000 claims abstract description 26
- 230000006378 damage Effects 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 230000004913 activation Effects 0.000 claims abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- -1 monosubstituted thiazolyl Chemical group 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 75
- 229960000311 ritonavir Drugs 0.000 claims description 72
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 71
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 37
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 37
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 108010079785 calpain inhibitors Proteins 0.000 claims description 28
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000002971 oxazolyl group Chemical group 0.000 claims description 27
- 125000000335 thiazolyl group Chemical group 0.000 claims description 26
- 230000005764 inhibitory process Effects 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 22
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 20
- 229960001852 saquinavir Drugs 0.000 claims description 18
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 16
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 16
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 16
- 229940121926 Calpain inhibitor Drugs 0.000 claims description 15
- 102100035037 Calpastatin Human genes 0.000 claims description 15
- 108010044208 calpastatin Proteins 0.000 claims description 15
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 15
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- 230000000302 ischemic effect Effects 0.000 claims description 13
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 12
- 229960001830 amprenavir Drugs 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229960001936 indinavir Drugs 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 229960000884 nelfinavir Drugs 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000028867 ischemia Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000008733 trauma Effects 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 7
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000004069 aziridinyl group Chemical group 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 5
- 230000005284 excitation Effects 0.000 claims description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 230000001732 thrombotic effect Effects 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 230000000798 anti-retroviral effect Effects 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 48
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 18
- 0 *C(C([Y])C(C[5*])N([H])C(=O)OC([6*])[7*])C(C[4*])N([H])C(=O)C([3*])N([H])C(=O)CC([1*])[2*] Chemical compound *C(C([Y])C(C[5*])N([H])C(=O)OC([6*])[7*])C(C[4*])N([H])C(=O)C([3*])N([H])C(=O)CC([1*])[2*] 0.000 description 13
- 208000006011 Stroke Diseases 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 10
- 230000000971 hippocampal effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108010010369 HIV Protease Proteins 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 210000002243 primary neuron Anatomy 0.000 description 9
- 102000005890 Spectrin Human genes 0.000 description 8
- 108010019965 Spectrin Proteins 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000006576 neuronal survival Effects 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 108010011767 m-calpain Proteins 0.000 description 4
- 108010068164 mu-calpain Proteins 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 3
- 108010005843 Cysteine Proteases Proteins 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 238000004617 QSAR study Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 2
- 230000006959 non-competitive inhibition Effects 0.000 description 2
- 229940072250 norvir Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000036967 uncompetitive effect Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XSRVIWTXGGNXSH-XGKFQTDJSA-N (2-morpholin-4-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,5s)-3-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)C(=O)OCC(N=1)=CSC=1N1CCOCC1 XSRVIWTXGGNXSH-XGKFQTDJSA-N 0.000 description 1
- WIQLCVMQNGDTAK-XGKFQTDJSA-N (2-morpholin-4-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,4s,5s)-4-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)OCC(N=1)=CSC=1N1CCOCC1 WIQLCVMQNGDTAK-XGKFQTDJSA-N 0.000 description 1
- MCCCPKRKPSEVAJ-WTOCPUKLSA-N (2-propan-2-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC1=CSC(C(C)C)=N1 MCCCPKRKPSEVAJ-WTOCPUKLSA-N 0.000 description 1
- MCCCPKRKPSEVAJ-NRQMHRBESA-N (2-propan-2-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC1=CSC(C(C)C)=N1 MCCCPKRKPSEVAJ-NRQMHRBESA-N 0.000 description 1
- MCCCPKRKPSEVAJ-QEUNAIBPSA-N (2-propan-2-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,4r,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC1=CSC(C(C)C)=N1 MCCCPKRKPSEVAJ-QEUNAIBPSA-N 0.000 description 1
- MCCCPKRKPSEVAJ-XDIGFQIYSA-N (2-propan-2-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC1=CSC(C(C)C)=N1 MCCCPKRKPSEVAJ-XDIGFQIYSA-N 0.000 description 1
- AKQIUGKMGJKZAC-QJANCWQKSA-N (2-propan-2-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,5s)-3-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)C(=O)OCC1=CSC(C(C)C)=N1 AKQIUGKMGJKZAC-QJANCWQKSA-N 0.000 description 1
- OLQPSFXWEYZQON-QJANCWQKSA-N (2-propan-2-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,4s,5s)-4-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)OCC1=CSC(C(C)C)=N1 OLQPSFXWEYZQON-QJANCWQKSA-N 0.000 description 1
- QAEUBSVYBCPTFI-IJLINHMISA-N (2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 QAEUBSVYBCPTFI-IJLINHMISA-N 0.000 description 1
- QAEUBSVYBCPTFI-AGGIAQGOSA-N (2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 QAEUBSVYBCPTFI-AGGIAQGOSA-N 0.000 description 1
- QAEUBSVYBCPTFI-PMUGGPHNSA-N (2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,4r,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 QAEUBSVYBCPTFI-PMUGGPHNSA-N 0.000 description 1
- QAEUBSVYBCPTFI-ZTTXAYQISA-N (2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 QAEUBSVYBCPTFI-ZTTXAYQISA-N 0.000 description 1
- QKTQUWORCBPDTH-XGKFQTDJSA-N (2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,3s,5s)-3-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 QKTQUWORCBPDTH-XGKFQTDJSA-N 0.000 description 1
- WXBCHXIPGSJFMX-XGKFQTDJSA-N (2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methyl n-[(2s)-1-[[(2s,4s,5s)-4-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 WXBCHXIPGSJFMX-XGKFQTDJSA-N 0.000 description 1
- AOMZDQMIOCTPQP-QHQMVRJISA-N (2s)-4-(1-benzofuran-2-ylmethyl)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butylpiperazine-2-carboxamide Chemical compound C([C@H](C[C@H](O)CN1CCN(CC=2OC3=CC=CC=C3C=2)C[C@H]1C(=O)NC(C)(C)C)C(=O)N[C@H]1C2=CC=CC=C2C[C@H]1O)C1=CC=CC=C1 AOMZDQMIOCTPQP-QHQMVRJISA-N 0.000 description 1
- LMSMDTBSAFDWMO-MKKRQWMVSA-N (3-propan-2-yl-1,2-oxazol-5-yl)methyl n-[(2s)-1-[[(2s,4s,5s)-4-hydroxy-1,6-diphenyl-5-(1,2-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)OCC1=CC(C(C)C)=NO1 LMSMDTBSAFDWMO-MKKRQWMVSA-N 0.000 description 1
- DQXIHYSYDBJBLO-IJLINHMISA-N 1,2-oxazol-5-ylmethyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DQXIHYSYDBJBLO-IJLINHMISA-N 0.000 description 1
- XMFOZNXNGZDMIY-IJLINHMISA-N 1,2-oxazol-5-ylmethyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 XMFOZNXNGZDMIY-IJLINHMISA-N 0.000 description 1
- DQXIHYSYDBJBLO-PMUGGPHNSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DQXIHYSYDBJBLO-PMUGGPHNSA-N 0.000 description 1
- XMFOZNXNGZDMIY-PMUGGPHNSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 XMFOZNXNGZDMIY-PMUGGPHNSA-N 0.000 description 1
- DQXIHYSYDBJBLO-AGGIAQGOSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DQXIHYSYDBJBLO-AGGIAQGOSA-N 0.000 description 1
- XMFOZNXNGZDMIY-AGGIAQGOSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 XMFOZNXNGZDMIY-AGGIAQGOSA-N 0.000 description 1
- DQXIHYSYDBJBLO-ZTTXAYQISA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DQXIHYSYDBJBLO-ZTTXAYQISA-N 0.000 description 1
- GZAFSZHUMSOMAK-LCKUPXPRSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-1,6-diphenyl-5-[[(2s)-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]propanoyl]amino]hexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(COC(=O)N[C@@H](C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 GZAFSZHUMSOMAK-LCKUPXPRSA-N 0.000 description 1
- SWYCHDZOBGOXTG-WQMHXLODSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]propanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 SWYCHDZOBGOXTG-WQMHXLODSA-N 0.000 description 1
- CNTCHUHCIDQACG-XGKFQTDJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(2-morpholin-4-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)OCC(N=1)=CSC=1N1CCOCC1 CNTCHUHCIDQACG-XGKFQTDJSA-N 0.000 description 1
- BZQDZPJBCATHBJ-QJANCWQKSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)OCC1=CSC(C(C)C)=N1 BZQDZPJBCATHBJ-QJANCWQKSA-N 0.000 description 1
- DQOLBQCTSFAHHR-XGKFQTDJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 DQOLBQCTSFAHHR-XGKFQTDJSA-N 0.000 description 1
- OVOYZWVIAVWLCV-MKKRQWMVSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(3-propan-2-yl-1,2-oxazol-5-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)OCC1=CC(C(C)C)=NO1 OVOYZWVIAVWLCV-MKKRQWMVSA-N 0.000 description 1
- ZSLDFFQRNWMIEI-SNZVYYTPSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-phenyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CC=CC=C1 ZSLDFFQRNWMIEI-SNZVYYTPSA-N 0.000 description 1
- URZYETGCXBKKBB-OUUVOGBVSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-prop-1-enyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C=CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 URZYETGCXBKKBB-OUUVOGBVSA-N 0.000 description 1
- KPLMCQMVNJULEW-OUUVOGBVSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-prop-2-enyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(CC=C)=N1 KPLMCQMVNJULEW-OUUVOGBVSA-N 0.000 description 1
- QAPQSPKIUQOIOD-XGKFQTDJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yloxy-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OC(C)C)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 QAPQSPKIUQOIOD-XGKFQTDJSA-N 0.000 description 1
- YUSIHUYEPYAFCU-QJANCWQKSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(1,3-thiazol-2-yl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=NC=CS1 YUSIHUYEPYAFCU-QJANCWQKSA-N 0.000 description 1
- CKKHPYNWISWUTF-JPECBQHSSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(2-methylprop-1-enyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C=C(C)C)=N1 CKKHPYNWISWUTF-JPECBQHSSA-N 0.000 description 1
- ADFNSCSYDJYFMX-RONNFESSSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(3-methylbut-2-en-2-yl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)=C(C)C)=N1 ADFNSCSYDJYFMX-RONNFESSSA-N 0.000 description 1
- VANCTRAEOFAWIO-PTJKBRNVSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(pyrrolidin-1-ylmethyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CN1CCCC1 VANCTRAEOFAWIO-PTJKBRNVSA-N 0.000 description 1
- JUQOAKWPRPOIGO-DNPKDEDDSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-benzyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1=CC=CC=C1 JUQOAKWPRPOIGO-DNPKDEDDSA-N 0.000 description 1
- MPGYCLRLGGQAKW-UYDQTSAYSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-but-2-en-2-yl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)=CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 MPGYCLRLGGQAKW-UYDQTSAYSA-N 0.000 description 1
- PFBXFVRXMNKDHT-UYDQTSAYSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclobutyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCC1 PFBXFVRXMNKDHT-UYDQTSAYSA-N 0.000 description 1
- UDGPWBFHJJVHPW-SNZVYYTPSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclohexyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCCCC1 UDGPWBFHJJVHPW-SNZVYYTPSA-N 0.000 description 1
- RFAYFIJKHLWGEA-RONNFESSSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclopentyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCCC1 RFAYFIJKHLWGEA-RONNFESSSA-N 0.000 description 1
- HLFNOGGDWSOUQZ-XGKFQTDJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclopropyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CC1 HLFNOGGDWSOUQZ-XGKFQTDJSA-N 0.000 description 1
- GBSIJIADHKSXPT-UDRKEFQJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethenyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C=C)=N1 GBSIJIADHKSXPT-UDRKEFQJSA-N 0.000 description 1
- DOPGIKAEBNMTIO-QJANCWQKSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethoxy-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OCC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 DOPGIKAEBNMTIO-QJANCWQKSA-N 0.000 description 1
- JECKUYVYEKIUQG-UDRKEFQJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2ON=CC=2)CC=2C=CC=CC=2)=C1 JECKUYVYEKIUQG-UDRKEFQJSA-N 0.000 description 1
- IBJHEHIUEYPOJS-LKZKAFSPSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[2-(dimethylamino)-1,3-thiazol-4-yl]methoxycarbonylamino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)OCC1=CSC(N(C)C)=N1 IBJHEHIUEYPOJS-LKZKAFSPSA-N 0.000 description 1
- SPNAUPXNKPODGZ-DNPKDEDDSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclohexylmethyl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1CCCCC1 SPNAUPXNKPODGZ-DNPKDEDDSA-N 0.000 description 1
- RVZYTGLZXFPTJY-RONNFESSSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclopenten-1-yl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CCCC1 RVZYTGLZXFPTJY-RONNFESSSA-N 0.000 description 1
- BERSDLOOOPBQQB-ZJPUNSCJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclopentylmethyl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1CCCC1 BERSDLOOOPBQQB-ZJPUNSCJSA-N 0.000 description 1
- JMOSUEBVFPVYPV-OUUVOGBVSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(CN(C)C)=N1 JMOSUEBVFPVYPV-OUUVOGBVSA-N 0.000 description 1
- WPABCLURSYDBFO-MAUIRPMDSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[4-(cyclopenten-1-yl)-5h-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1(C=2CCCC=2)CSC=N1 WPABCLURSYDBFO-MAUIRPMDSA-N 0.000 description 1
- CKEXCQBVAXQPIP-UYDQTSAYSA-N 1,2-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[ethyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)CC=1C=CC=CC=1)C(=O)N(CC)CC1=CSC(C(C)C)=N1 CKEXCQBVAXQPIP-UYDQTSAYSA-N 0.000 description 1
- UXIKQIYEFZHYBU-XGKFQTDJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,4s,5s)-4-hydroxy-5-[[(2s)-3-methyl-2-[(2-morpholin-4-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)OCC(N=1)=CSC=1N1CCOCC1 UXIKQIYEFZHYBU-XGKFQTDJSA-N 0.000 description 1
- YUXGIRHTYTYSJY-QJANCWQKSA-N 1,2-oxazol-5-ylmethyl n-[(2s,4s,5s)-4-hydroxy-5-[[(2s)-3-methyl-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)OCC1=CSC(C(C)C)=N1 YUXGIRHTYTYSJY-QJANCWQKSA-N 0.000 description 1
- FXGYRNAECBLOEK-XGKFQTDJSA-N 1,2-oxazol-5-ylmethyl n-[(2s,4s,5s)-4-hydroxy-5-[[(2s)-3-methyl-2-[(2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 FXGYRNAECBLOEK-XGKFQTDJSA-N 0.000 description 1
- BHLLWZSKOCAZAS-LKZKAFSPSA-N 1,2-oxazol-5-ylmethyl n-[(2s,4s,5s)-5-[[(2s)-2-[[2-(dimethylamino)-1,3-thiazol-4-yl]methoxycarbonylamino]-3-methylbutanoyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1ON=CC=1)C(=O)OCC1=CSC(N(C)C)=N1 BHLLWZSKOCAZAS-LKZKAFSPSA-N 0.000 description 1
- IXJGAYHSDYOZNX-SYRRBAGUSA-N 1,2-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[[2-(2-phenylethenyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C=CC1=CC=CC=C1 IXJGAYHSDYOZNX-SYRRBAGUSA-N 0.000 description 1
- RIWZRVYOJOSMHN-PMUGGPHNSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 RIWZRVYOJOSMHN-PMUGGPHNSA-N 0.000 description 1
- RIWZRVYOJOSMHN-ZTTXAYQISA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 RIWZRVYOJOSMHN-ZTTXAYQISA-N 0.000 description 1
- FELUQTGUXTUVKS-LCKUPXPRSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-1,6-diphenyl-5-[[(2s)-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]propanoyl]amino]hexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(COC(=O)N[C@@H](C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 FELUQTGUXTUVKS-LCKUPXPRSA-N 0.000 description 1
- HUPYSLHHZDCQCR-LKZKAFSPSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-2-[[(2-methoxy-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 HUPYSLHHZDCQCR-LKZKAFSPSA-N 0.000 description 1
- GKFODLLJMJGYSL-WQMHXLODSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]propanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 GKFODLLJMJGYSL-WQMHXLODSA-N 0.000 description 1
- YKAKJOLYUBINTP-OUUVOGBVSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-prop-1-enyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C=CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 YKAKJOLYUBINTP-OUUVOGBVSA-N 0.000 description 1
- DXZPFHCLYLMWGS-OUUVOGBVSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-prop-2-enyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(CC=C)=N1 DXZPFHCLYLMWGS-OUUVOGBVSA-N 0.000 description 1
- XSVKBPBPZISPHE-XGKFQTDJSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yloxy-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OC(C)C)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 XSVKBPBPZISPHE-XGKFQTDJSA-N 0.000 description 1
- FKMQOTCGXAKBKF-OUUVOGBVSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CCC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 FKMQOTCGXAKBKF-OUUVOGBVSA-N 0.000 description 1
- UYZFOHNMASIPQK-QJANCWQKSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(1,3-thiazol-2-yl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=NC=CS1 UYZFOHNMASIPQK-QJANCWQKSA-N 0.000 description 1
- OWBKDJFIAVQMBF-YUZQSQGUSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(1,3-thiazol-2-ylmethyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1=NC=CS1 OWBKDJFIAVQMBF-YUZQSQGUSA-N 0.000 description 1
- CQCRRXICIYWZEM-QPMFNIJWSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(2-methylbutyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CC(C)CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 CQCRRXICIYWZEM-QPMFNIJWSA-N 0.000 description 1
- GWJILKQDJOVNHR-JPECBQHSSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(2-methylprop-1-enyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C=C(C)C)=N1 GWJILKQDJOVNHR-JPECBQHSSA-N 0.000 description 1
- OHVOWLPJXYJEOW-RONNFESSSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(3-methylbut-2-en-2-yl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)=C(C)C)=N1 OHVOWLPJXYJEOW-RONNFESSSA-N 0.000 description 1
- DPNUVTPNLPNOGZ-UYDQTSAYSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-but-2-en-2-yl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)=CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 DPNUVTPNLPNOGZ-UYDQTSAYSA-N 0.000 description 1
- YXDMZXJRETXQEQ-UYDQTSAYSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclobutyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCC1 YXDMZXJRETXQEQ-UYDQTSAYSA-N 0.000 description 1
- YQBBVRUXPQOAEE-SNZVYYTPSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclohexyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCCCC1 YQBBVRUXPQOAEE-SNZVYYTPSA-N 0.000 description 1
- CORQTBQAQNMESX-RONNFESSSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclopentyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCCC1 CORQTBQAQNMESX-RONNFESSSA-N 0.000 description 1
- KXPLBVAUOQYPRA-XGKFQTDJSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclopropyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CC1 KXPLBVAUOQYPRA-XGKFQTDJSA-N 0.000 description 1
- DCGJEFFVIVHXSN-UDRKEFQJSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethenyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C=C)=N1 DCGJEFFVIVHXSN-UDRKEFQJSA-N 0.000 description 1
- IQPLLQISQKLBIV-QJANCWQKSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethoxy-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OCC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 IQPLLQISQKLBIV-QJANCWQKSA-N 0.000 description 1
- XVIQINZGVHZGSN-UDRKEFQJSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SN=CC=2)CC=2C=CC=CC=2)=C1 XVIQINZGVHZGSN-UDRKEFQJSA-N 0.000 description 1
- UMJJKCJOIWTBIZ-LKZKAFSPSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[2-(dimethylamino)-1,3-thiazol-4-yl]methoxycarbonylamino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)OCC1=CSC(N(C)C)=N1 UMJJKCJOIWTBIZ-LKZKAFSPSA-N 0.000 description 1
- HSJSNBHXYMNNPB-SNZVYYTPSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclohexen-1-yl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CCCCC1 HSJSNBHXYMNNPB-SNZVYYTPSA-N 0.000 description 1
- GGLBBWZIAVMJSA-DNPKDEDDSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclohexylmethyl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1CCCCC1 GGLBBWZIAVMJSA-DNPKDEDDSA-N 0.000 description 1
- UKVUDVIKMFLRDA-RONNFESSSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclopenten-1-yl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CCCC1 UKVUDVIKMFLRDA-RONNFESSSA-N 0.000 description 1
- XGFZBFLEKUNEEG-ZJPUNSCJSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclopentylmethyl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1CCCC1 XGFZBFLEKUNEEG-ZJPUNSCJSA-N 0.000 description 1
- MUZUEZVRFCUVPZ-OUUVOGBVSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(CN(C)C)=N1 MUZUEZVRFCUVPZ-OUUVOGBVSA-N 0.000 description 1
- NPIGFZGGSIOXAI-DQZHFXBMSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[4-(cyclohexen-1-yl)-5h-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1(C=2CCCCC=2)CSC=N1 NPIGFZGGSIOXAI-DQZHFXBMSA-N 0.000 description 1
- BIJJDWPQPSEKLN-MAUIRPMDSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[4-(cyclopenten-1-yl)-5h-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1(C=2CCCC=2)CSC=N1 BIJJDWPQPSEKLN-MAUIRPMDSA-N 0.000 description 1
- CPSAITHCLQYFTR-UYDQTSAYSA-N 1,2-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[ethyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)CC=1C=CC=CC=1)C(=O)N(CC)CC1=CSC(C(C)C)=N1 CPSAITHCLQYFTR-UYDQTSAYSA-N 0.000 description 1
- RLGWITDMQSRHGZ-LKZKAFSPSA-N 1,2-thiazol-5-ylmethyl n-[(2s,4s,5s)-5-[[(2s)-2-[[2-(dimethylamino)-1,3-thiazol-4-yl]methoxycarbonylamino]-3-methylbutanoyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SN=CC=1)C(=O)OCC1=CSC(N(C)C)=N1 RLGWITDMQSRHGZ-LKZKAFSPSA-N 0.000 description 1
- PMYIFEAHEXPUGK-SYRRBAGUSA-N 1,3-oxazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[[2-(2-phenylethenyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C=CC1=CC=CC=C1 PMYIFEAHEXPUGK-SYRRBAGUSA-N 0.000 description 1
- OLYNFJGRABBWJN-IJLINHMISA-N 1,3-oxazol-5-ylmethyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 OLYNFJGRABBWJN-IJLINHMISA-N 0.000 description 1
- MTMIDHHGHOCHRE-IJLINHMISA-N 1,3-oxazol-5-ylmethyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 MTMIDHHGHOCHRE-IJLINHMISA-N 0.000 description 1
- OLYNFJGRABBWJN-PMUGGPHNSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 OLYNFJGRABBWJN-PMUGGPHNSA-N 0.000 description 1
- MTMIDHHGHOCHRE-PMUGGPHNSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 MTMIDHHGHOCHRE-PMUGGPHNSA-N 0.000 description 1
- OLYNFJGRABBWJN-AGGIAQGOSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 OLYNFJGRABBWJN-AGGIAQGOSA-N 0.000 description 1
- MTMIDHHGHOCHRE-AGGIAQGOSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 MTMIDHHGHOCHRE-AGGIAQGOSA-N 0.000 description 1
- OLYNFJGRABBWJN-ZTTXAYQISA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 OLYNFJGRABBWJN-ZTTXAYQISA-N 0.000 description 1
- MTMIDHHGHOCHRE-ZTTXAYQISA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 MTMIDHHGHOCHRE-ZTTXAYQISA-N 0.000 description 1
- KBQXWKKMLHKSQD-LCKUPXPRSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-1,6-diphenyl-5-[[(2s)-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]propanoyl]amino]hexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(COC(=O)N[C@@H](C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 KBQXWKKMLHKSQD-LCKUPXPRSA-N 0.000 description 1
- IDVXFSNNIDTRLR-LKZKAFSPSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-2-[[(2-methoxy-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 IDVXFSNNIDTRLR-LKZKAFSPSA-N 0.000 description 1
- HGVUIDPFDHKIIJ-WQMHXLODSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]propanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 HGVUIDPFDHKIIJ-WQMHXLODSA-N 0.000 description 1
- CQPDNUGTKWQOPK-XGKFQTDJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(2-morpholin-4-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)OCC(N=1)=CSC=1N1CCOCC1 CQPDNUGTKWQOPK-XGKFQTDJSA-N 0.000 description 1
- HNKZOJRKPJUGAH-QJANCWQKSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)OCC1=CSC(C(C)C)=N1 HNKZOJRKPJUGAH-QJANCWQKSA-N 0.000 description 1
- HPEIBQUCRJDCGI-XGKFQTDJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 HPEIBQUCRJDCGI-XGKFQTDJSA-N 0.000 description 1
- VYTNHZLHRCYCIF-MKKRQWMVSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[(3-propan-2-yl-1,2-oxazol-5-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)OCC1=CC(C(C)C)=NO1 VYTNHZLHRCYCIF-MKKRQWMVSA-N 0.000 description 1
- JHCOASSLSVYRAD-SNZVYYTPSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-phenyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CC=CC=C1 JHCOASSLSVYRAD-SNZVYYTPSA-N 0.000 description 1
- UNMOZDNYFCOHCB-OUUVOGBVSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-prop-1-enyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C=CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 UNMOZDNYFCOHCB-OUUVOGBVSA-N 0.000 description 1
- PGOUKCPKVRTPDA-OUUVOGBVSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-prop-2-enyl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(CC=C)=N1 PGOUKCPKVRTPDA-OUUVOGBVSA-N 0.000 description 1
- RTUDJJASMWSFNY-XGKFQTDJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yloxy-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(OC(C)C)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 RTUDJJASMWSFNY-XGKFQTDJSA-N 0.000 description 1
- FKRDPRNKTWDYFJ-QPMFNIJWSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(2-methylbutyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CC(C)CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 FKRDPRNKTWDYFJ-QPMFNIJWSA-N 0.000 description 1
- KUJZPUYHVSHIJT-JPECBQHSSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(2-methylprop-1-enyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C=C(C)C)=N1 KUJZPUYHVSHIJT-JPECBQHSSA-N 0.000 description 1
- YMRCTRBVSKALPD-RONNFESSSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(3-methylbut-2-en-2-yl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)=C(C)C)=N1 YMRCTRBVSKALPD-RONNFESSSA-N 0.000 description 1
- MVYXXROENCWMCD-PTJKBRNVSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[[2-(pyrrolidin-1-ylmethyl)-1,3-thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CN1CCCC1 MVYXXROENCWMCD-PTJKBRNVSA-N 0.000 description 1
- QWEIQJXNABPEMJ-UYDQTSAYSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-but-2-en-2-yl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)=CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 QWEIQJXNABPEMJ-UYDQTSAYSA-N 0.000 description 1
- SUGPLCUEOBTSNQ-SNZVYYTPSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclohexyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCCCC1 SUGPLCUEOBTSNQ-SNZVYYTPSA-N 0.000 description 1
- HBWYZODNPDGMKF-RONNFESSSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-cyclopentyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1CCCC1 HBWYZODNPDGMKF-RONNFESSSA-N 0.000 description 1
- SBJOUCSIFPIRCA-UDRKEFQJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethenyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C=C)=N1 SBJOUCSIFPIRCA-UDRKEFQJSA-N 0.000 description 1
- WGVRMEMPVOUMQN-UDRKEFQJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[(2-ethyl-1,3-thiazol-4-yl)methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CC)=NC(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2OC=NC=2)CC=2C=CC=CC=2)=C1 WGVRMEMPVOUMQN-UDRKEFQJSA-N 0.000 description 1
- VFVRLGHYOBVEDC-LKZKAFSPSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[2-(dimethylamino)-1,3-thiazol-4-yl]methoxycarbonylamino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)OCC1=CSC(N(C)C)=N1 VFVRLGHYOBVEDC-LKZKAFSPSA-N 0.000 description 1
- YPSKTIWIXCQQFL-DNPKDEDDSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclohexylmethyl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1CC1CCCCC1 YPSKTIWIXCQQFL-DNPKDEDDSA-N 0.000 description 1
- ITRAHVLBMGFZHT-RONNFESSSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-(cyclopenten-1-yl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CCCC1 ITRAHVLBMGFZHT-RONNFESSSA-N 0.000 description 1
- ZQCKPGQFDJOMKS-OUUVOGBVSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(CN(C)C)=N1 ZQCKPGQFDJOMKS-OUUVOGBVSA-N 0.000 description 1
- BGMOULRAUZSOAB-DQZHFXBMSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[4-(cyclohexen-1-yl)-5h-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1(C=2CCCCC=2)CSC=N1 BGMOULRAUZSOAB-DQZHFXBMSA-N 0.000 description 1
- IWGQUCWDWSCXNV-MAUIRPMDSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[[4-(cyclopenten-1-yl)-5h-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1(C=2CCCC=2)CSC=N1 IWGQUCWDWSCXNV-MAUIRPMDSA-N 0.000 description 1
- XQLAHBFPEZUXCS-UYDQTSAYSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s)-5-[[(2s)-2-[[ethyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(CC)CC1=CSC(C(C)C)=N1 XQLAHBFPEZUXCS-UYDQTSAYSA-N 0.000 description 1
- HNDSHAVSWMPAIB-SNZVYYTPSA-N 1,3-oxazol-5-ylmethyl n-[(2s,3s,5s,7s)-5-benzyl-7-[[[2-(cyclohexen-1-yl)-1,3-thiazol-4-yl]methyl-methylcarbamoyl]amino]-3-hydroxy-8-methyl-6-oxo-1-phenylnonan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC(N=1)=CSC=1C1=CCCCC1 HNDSHAVSWMPAIB-SNZVYYTPSA-N 0.000 description 1
- VMOMDLZJBSITID-XGKFQTDJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,4s,5s)-4-hydroxy-5-[[(2s)-3-methyl-2-[(2-morpholin-4-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)OCC(N=1)=CSC=1N1CCOCC1 VMOMDLZJBSITID-XGKFQTDJSA-N 0.000 description 1
- NQTAHOJAXINYQJ-QJANCWQKSA-N 1,3-oxazol-5-ylmethyl n-[(2s,4s,5s)-4-hydroxy-5-[[(2s)-3-methyl-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)OCC1=CSC(C(C)C)=N1 NQTAHOJAXINYQJ-QJANCWQKSA-N 0.000 description 1
- FIBZURWHQWHNFM-XGKFQTDJSA-N 1,3-oxazol-5-ylmethyl n-[(2s,4s,5s)-4-hydroxy-5-[[(2s)-3-methyl-2-[(2-pyrrolidin-1-yl-1,3-thiazol-4-yl)methoxycarbonylamino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)OCC(N=1)=CSC=1N1CCCC1 FIBZURWHQWHNFM-XGKFQTDJSA-N 0.000 description 1
- KZBKHBIEDMBFIJ-LKZKAFSPSA-N 1,3-oxazol-5-ylmethyl n-[(2s,4s,5s)-5-[[(2s)-2-[[2-(dimethylamino)-1,3-thiazol-4-yl]methoxycarbonylamino]-3-methylbutanoyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1OC=NC=1)C(=O)OCC1=CSC(N(C)C)=N1 KZBKHBIEDMBFIJ-LKZKAFSPSA-N 0.000 description 1
- KNMBQRCINKLSIT-IREJJKFYSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]propanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@@H](O)[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)=C1 KNMBQRCINKLSIT-IREJJKFYSA-N 0.000 description 1
- DNEUHCAKTBEUHJ-IJLINHMISA-N 1,3-thiazol-5-ylmethyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DNEUHCAKTBEUHJ-IJLINHMISA-N 0.000 description 1
- ZNZQCMSJVHZYGP-REZIECOHSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-1,6-diphenyl-5-[[(2s)-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]propanoyl]amino]hexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(COC(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@H](O)[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)=C1 ZNZQCMSJVHZYGP-REZIECOHSA-N 0.000 description 1
- KNMBQRCINKLSIT-JWJTUTPFSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]propanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@H](O)[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)=C1 KNMBQRCINKLSIT-JWJTUTPFSA-N 0.000 description 1
- ZNZQCMSJVHZYGP-DDRBTIHYSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-1,6-diphenyl-5-[[(2s)-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]propanoyl]amino]hexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(COC(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@@H](O)[C@@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)=C1 ZNZQCMSJVHZYGP-DDRBTIHYSA-N 0.000 description 1
- DNEUHCAKTBEUHJ-AGGIAQGOSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DNEUHCAKTBEUHJ-AGGIAQGOSA-N 0.000 description 1
- ZNZQCMSJVHZYGP-NELKFLMZSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-1,6-diphenyl-5-[[(2s)-2-[(2-propan-2-yl-1,3-thiazol-4-yl)methoxycarbonylamino]propanoyl]amino]hexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(COC(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@H](O)[C@@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)=C1 ZNZQCMSJVHZYGP-NELKFLMZSA-N 0.000 description 1
- KNMBQRCINKLSIT-LAMIVESZSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]propanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@H](O)[C@@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)=C1 KNMBQRCINKLSIT-LAMIVESZSA-N 0.000 description 1
- DNEUHCAKTBEUHJ-ZTTXAYQISA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-oxazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C(=O)N(C)CC1=COC(C(C)C)=N1 DNEUHCAKTBEUHJ-ZTTXAYQISA-N 0.000 description 1
- VKZXSCAFBACBKO-UHFFFAOYSA-N 1,6-diphenylhexan-3-ol Chemical compound C=1C=CC=CC=1CCC(O)CCCC1=CC=CC=C1 VKZXSCAFBACBKO-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- QGXQKGLWWDUOEY-UHFFFAOYSA-N 3-n-hydroxybicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide Chemical compound C1C2C=CC1C(C(=O)N)C2C(=O)NO QGXQKGLWWDUOEY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical class COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RYGPIQHJKAUKAF-UHFFFAOYSA-N CC(C)(C)NC(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(=O)NC1C2=C(C=CC=C2)CC1O Chemical compound CC(C)(C)NC(O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(=O)NC1C2=C(C=CC=C2)CC1O RYGPIQHJKAUKAF-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-FDEOAKKQSA-N CC(C)C1=NC(CN(C)C(=O)NC(C(=O)N[C@@H](CC2=CC=CC=C2)CC(O)[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)C(C)C)=CS1 Chemical compound CC(C)C1=NC(CN(C)C(=O)NC(C(=O)N[C@@H](CC2=CC=CC=C2)CC(O)[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)C(C)C)=CS1 NCDNCNXCDXHOMX-FDEOAKKQSA-N 0.000 description 1
- XSYCWRFGBAWEPU-UHFFFAOYSA-N CC(C)CN(CC(O)C(CC1=CC=CC=C1)NC(=O)OC1CCOC1)SC1=CC=C(N)C=C1 Chemical compound CC(C)CN(CC(O)C(CC1=CC=CC=C1)NC(=O)OC1CCOC1)SC1=CC=C(N)C=C1 XSYCWRFGBAWEPU-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-YXMNFLNXSA-N CC1=C(C(=O)N[C@H](CSC2=CC=CC=C2)[C@@H](O)CN2CC3CCCCC3C[C@H]2C(=O)NC(C)(C)C)C=CC=C1O Chemical compound CC1=C(C(=O)N[C@H](CSC2=CC=CC=C2)[C@@H](O)CN2CC3CCCCC3C[C@H]2C(=O)NC(C)(C)C)C=CC=C1O QAGYKUNXZHXKMR-YXMNFLNXSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- SUWMPHGMYGFQAE-WZJLIZBTSA-N OCC1=CC=C(CN2CN(CC3=CC=C(CO)C=C3)[C@H](C3=CC=CC=C3)[C@H](O)[C@@H](O)[C@H]2CC2=CC=CC=C2)C=C1 Chemical compound OCC1=CC=C(CN2CN(CC3=CC=C(CO)C=C3)[C@H](C3=CC=CC=C3)[C@H](O)[C@@H](O)[C@H]2CC2=CC=CC=C2)C=C1 SUWMPHGMYGFQAE-WZJLIZBTSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JARNKPQDFXUJTE-UHFFFAOYSA-N [3-hydroxy-5-[[3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamic acid Chemical compound C=1C=CC=CC=1CC(NC(O)=O)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 JARNKPQDFXUJTE-UHFFFAOYSA-N 0.000 description 1
- KYPIMBQCWFYWQH-ACYIFXAXSA-M [H][C@@]12CCCC[C@]1([H])CC(C[C@H](O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=CC=CC=C3C=C1)[C@H](C(=O)[N-]CCCC)C2 Chemical compound [H][C@@]12CCCC[C@]1([H])CC(C[C@H](O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=CC=CC=C3C=C1)[C@H](C(=O)[N-]CCCC)C2 KYPIMBQCWFYWQH-ACYIFXAXSA-M 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 102000028861 calmodulin binding Human genes 0.000 description 1
- 108091000084 calmodulin binding Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000006726 chronic neurodegeneration Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 229940088900 crixivan Drugs 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- LONYOMRPNGXPGP-UHFFFAOYSA-N ethene-1,1-diol Chemical group [CH2][C](O)O LONYOMRPNGXPGP-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- NUBQKPWHXMGDLP-BDEHJDMKSA-N indinavir sulfate Chemical compound OS(O)(=O)=O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 NUBQKPWHXMGDLP-BDEHJDMKSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940088976 invirase Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 1
- 229960005230 nelfinavir mesylate Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003542 saquinavir mesylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000006967 uncompetitive inhibition Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940023080 viracept Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- This invention relates to enzymatic inhibitors, particularly calpain inhibitors, and more particularly, calpain inhibition by HIV protease inhibitors.
- Calpains are mammalian calcium-dependent neutral cysteine proteases involved in programmed cell death (apoptosis). Calpains are referred to as cysteine proteases because they include a cysteine residue that plays a critical role in the catalytic process. In the presence of calcium, a cysteine protease catalytic triad forms when three amino acid residues (Cys105, His262, and Asn 286) are brought together in the active site.
- calpain Two major classes of calpains are known, ⁇ -calpain and m-calpain, which differ in their sensitivities toward calcium. Some tissue-specific forms of calpain also have been identified. Substrates of calpain include cellular proteins such as cytoskeletal proteins, membrane-bound receptors, calmodulin binding proteins, myofibrillar proteins, enzymes, and transcription factors.
- Calpain can become activated under ischemic conditions. It has been proposed that ischemia overactivates cellular membrane receptors, which causes an influx of calcium ions into the cell. This influx activates calcium-dependent enzymes, including calpains, and the calpains begin digesting cellular proteins, which contributes to cell death.
- Inhibition of calpain has provided therapeutic possibilities for a number of different diseases, including cerebral ischemia (particularly strokes), traumatic brain injury, subarachnoid hemorrhage, chronic neurodegeneration (e.g., Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis), Alzheimer's disease, cardiac ischemia (particularly myocardial infarction), muscular dystrophy, cataracts, thrombotic platelet aggregation, restenosis, and joint inflammation (particularly arthritis).
- cerebral ischemia particularly strokes
- traumatic brain injury traumatic brain injury
- subarachnoid hemorrhage chronic neurodegeneration
- chronic neurodegeneration e.g., Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis
- Alzheimer's disease e.g., Alzheimer's disease, cardiac ischemia (particularly myocardial infarction)
- muscular dystrophy e.g., cataracts, thrombotic platelet aggregation,
- HIV human immunodeficiency virus
- AIDS acquired immunodeficiency syndrome
- HIV protease is an aspartyl protease that plays a central role in viral processing by cleaving the HIV GAG and GAG-POL polypeptides to produce mature viral core proteins and virus-specific enzymes.
- the HIV protease is called an aspartyl protease due to an important aspartyl residue in the active site that hydrolyzes the peptide bond of its substrate.
- HIV protease inhibitors include ritonavir, saquinavir, indinavir, nelfinavir, and amprenavir. Numerous other HIV protease inhibitors are currently being tested in humans, but have not yet been approved by the United States Food and Drug Administration (FDA) for use against HIV, including ABT378, BMS232632, DMP450, GW433908, L-756,423, and timpranavir. Other HIV protease inhibitors have been disclosed in the patent literature, including: Martin et al., U.S. Pat. No. 5,196,438; Vacca et al., U.S. Pat. No. 5,413,999; Dressman et al., U.S.
- HIV inhibitors are used to inhibit calpain activity.
- the calpain inhibitor is an analog of or compound related to an HIV protease inhibitor.
- a calpain may be inhibited by contacting the calpain with a disclosed inhibitor, such as an HIV protease inhibitor, analog, or related compound.
- a disclosed inhibitor such as an HIV protease inhibitor, analog, or related compound.
- the calpain inhibitor is administered in therapeutically effective amounts to inhibit calpains within cells of subjects.
- the calpain inhibitor is a compound having one or more of the following structures or clinical names, without reference to the ability of that compound to inhibit HIV protease activity:
- R 1 is monosubstituted thiazolyl, mono substituted oxazolyl, monosubstituted isoxazolyl, or monosubstituted isothiazolyl; and wherein the substituent is selected from: lower alkyl; lower alkenyl; cycloalkyl; cycloalkylalkyl; cycloalkenyl; cycloalkenylalkyl; heterocyclic, wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substitu
- n 1, 2 or 3;
- R 2 is hydrogen or a lower alkyl
- R 3 is a lower alkyl
- R 4 and R 5 are independently selected from phenyl, thiazolyl, and oxazolyl, wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy, and thioalkoxy;
- R 6 is hydrogen or lower alkyl
- R 7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl, wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with lower alkyl;
- X is hydrogen and Y is —OH, or X is —OH and Y is hydrogen, with the proviso that X is hydrogen and Y is —OH when Z is —N(R 8 )— and R 7 is unsubstituted, and with the proviso that X is hydrogen and Y is —OH when R 3 is methyl and R 7 is unsubstituted; and
- Z is absent, 'O—, 'S—, —CH 2 — or —N(R 8 )— wherein R 8 is a lower alkyl, cycloalkyl, —OH or —NHR 9 , wherein R 9 is hydrogen, lower alkyl or an N-protecting group; or
- R is benzyloxycarbonyl or 2-quinolylcarbonyl
- Subjects at risk of suffering calpain-mediated physiological damage may be identified and administered an HIV protease inhibitor, or another compound disclosed herein, following an event associated with activation of calpain, such as ischemia in the cardiovascular (including the neurovascular) system, or the myocardial or neural tissues which these systems perfuse.
- Some embodiments include treating or preventing calpain-mediated physiological damage in a subject.
- calpain-mediated physiological damage is treated by administering to a subject a therapeutically effective amount of a pharmaceutical composition having at least one protease inhibitor.
- pharmaceutical compositions include those with plural HIV protease inhibitors; pharmaceutically compatible carriers, agents, counterions, adjuvants, or vehicles; and/or other calpain inhibitors (in addition to the compounds disclosed herein). Treatments may be prophylactic or reparative.
- therapeutically effective amounts of compounds include amounts that provide an inhibition constant, K i , for inhibition of calpain less than or equal to about 11 ⁇ M. Additionally, therapeutically effective doses of compounds may be administered to a subject for a limited period of time, such as about a month, a week, or even less than about 72 hours.
- the pharmaceutical compositions can be used to treat a variety of conditions or diseases associated with calpain activation, including cardiovascular diseases.
- the treated condition is ischemia, such as myocardial or neural ischemia, resulting from decreased oxygenation of these tissues, as may occur in myocardial infarction, coronary stenosis or vasospasm, cerebrovascular accidents, such as ischemic or hemorrhagic stroke, and neurological trauma.
- An “animal” is a living multicellular vertebrate organism, a category which includes, for example, mammals and birds.
- amino refers to a chemical functionality —NR 1 R 2 where R 1 and R 2 are independently hydrogen, alkyl, or aryl.
- activated ester derivative refers to acid halides, such as acid chlorides, and activated esters including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides (such as isobutyloxycarbonylchloride), N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters, N-hydroxy-5-norbornene-2,3-dicarboxamide derived esters, and 2,4,5-trichlorophenol derived esters and the like.
- activated esters including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides (such as isobutyloxycarbonylchloride), N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters, N-hydroxy-5-norborn
- an “analog” is a molecule that is structurally similar to another molecule but which differs slightly in chemical structure from a parent compound, for example by the replacement of one atom by an atom of a different element, or by the substitution of one functional group for another.
- Examples include, but are not limited to, a homolog (which differs by an increment in the chemical structure, such as a difference in the length of an alkyl chain), a molecular fragment, a structure that differs by one or more functional groups, or a change in ionization.
- Structural analogs are often found using quantitative structure activity relationships (QSAR), with techniques such as those disclosed in Remington: The Science and Practice of Pharmacology, 19 th Edition (1995), chapter 28.
- a derivative is a biologically active molecule derived from the base molecular structure.
- a mimetic is a biomolecule that mimics the activity of another biologically active molecule.
- Biologically active molecules can include both chemical structures and peptides that mimic the calpain inhibition activities of the compounds disclosed herein, regardless of whether they also inhibit HIV protease activity.
- alkylamino refers to a lower alkyl radical appended to an —NH radical.
- alkoxy refers to a substituted or unsubstituted alkoxy, where an alkoxy has the structure —O—R, where R is a substituted or unsubstituted alkyl. In an unsubstituted alkoxy, the R is an unsubstituted alkyl.
- substituted alkoxy refers to a group having the structure —O—R, where R is alkyl which is substituted with a non-interfering substituent.
- Lower alkoxy refers to any alkoxy in which R is a lower alkyl.
- Thioalkoxy refers to —S—R, where R is substituted or unsubstituted alkyl.
- alkoxyalkyl refers to an alkoxy group appended to a lower alkyl radical.
- alkyl refers to a cyclic, branched, or straight chain alkyl group containing only carbon and hydrogen, which, unless otherwise described, contains one to twelve carbon atoms. This term is further exemplified by groups such as methyl, ethyl, n-propyl, isobutyl, t-butyl, pentyl, pivalyl, heptyl, adamantyl, and cyclopentyl.
- Alkyl groups can be unsubstituted or substituted with one or more substituents, for example halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
- substituents for example halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
- aryl refers to a monovalent unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl), which can optionally be unsubstituted or substituted with, for example, halogen, alkyl, alkoxy, mercapto (—SH), alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
- Calpain mediated physiological damage refers to pathological conditions mediated by calpain. Such conditions can include a variety of ischemic events (such as myocardial or cerebral ischemia), as well as non-ischemic disorders (such as Alzheimer's disease or muscular dystrophy).
- ischemic events such as myocardial or cerebral ischemia
- non-ischemic disorders such as Alzheimer's disease or muscular dystrophy
- Carbonyl containing group refers to any substituent containing a carbon-oxygen double bond, including substituents based on —COR where R is an alkyl, lower alkyl, hydroxyl, or a secondary, tertiary, or quaternary amine. The term also encompasses oximes and hydrazones.
- carbonyl-containing group refers to —R 1 COR 2 groups wherein R 2 is alkyl, lower alkyl, hydroxyl, or secondary, tertiary, or quaternary amine and R 1 is alkylene, such as methylene (—CH 2 —). Examples include —COOH, —CH 2 COOH, —CH 2 COOCH 3 , —CH 2 CONH 2 , and —CH 2 CON(CH 3 ) 2 .
- Carboxyl refers to the radical —COOH, and substituted carboxyl refers to —COR where R is alkyl, lower alkyl or a carboxylic acid or ester.
- cycloalkyl refers to an aliphatic ring having 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.
- cycloalkylalkyl refers to a cycloalkyl group appended to a lower alkyl radical, including, but not limited to, cyclohexylmethyl.
- cycloalkenyl refers to an aliphatic ring having 5 to 7 carbon atoms and also having one carbon-carbon double bond including, but not limited to, cyclopentenyl and cyclohexenyl.
- cycloalkenyalkyl refers to a cycloalkenyl group appended to a lower alkyl radical including, but not limited to, cyclopentenylmethyl and cyclohexenylmethyl.
- dialkylamino refers to —N—R 1 —R 2 wherein R 1 and R 2 are independently selected from lower alkyl groups.
- dialkylaminoalkyl refers to —N—R 1 —R 2 , which is appended to a lower alkyl radical, wherein R 1 and R 2 are independently selected from lower alkyl groups.
- halo or refers to fluoro, bromo, chloro and iodo substituents.
- halogen refers to fluorine, bromine, chlorine, and iodine.
- a “heart attack” is a general term encompassing cardiac traumas or diseases, such as myocardial infarction, angina, or cardiac arrhythmia. It is often, but not invariable, the result of cardiovascular disease, such as that seen in atherosclerosis.
- heterocycle refers to a monovalent saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g. benzyl, morpholino, pyridyl, or furyl), or multiple condensed rings (e.g. naphthyl, quinolinyl, indolizinyl or benzo[b]thienyl), and having at least one heteroatom, (defined as N, O, P, or S) within the ring.
- a single ring e.g. benzyl, morpholino, pyridyl, or furyl
- multiple condensed rings e.g. naphthyl, quinolinyl, indolizinyl or benzo[b]thienyl
- heteroatom defined as N, O, P, or S
- a heterocycle can optionally be unsubstituted or substituted with, for example, halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
- Examples include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl.
- heterocyclicalkyl refers to a heterocyclic group appended to a lower alkyl radical including, but not limited to, pyrrolidinylmethyl and morpholinylmethyl.
- HIV disease refers to a well recognized constellation of signs and symptoms (including the development of opportunistic infections) in persons who are infected by a human immunodeficiency virus (HIV), as determined by antibody or western blot studies. Laboratory findings associated with this disease are a progressive decline in T-helper cells.
- HIV protease inhibitor refers to compounds which inhibit the enzymatic activity of an HIV protease. Examples include, but are not limited to, the HIV protease inhibitors disclosed in Table 1.
- “Hydroxyl” refers to —OH.
- “Hydroxyalkyl” refers to —R—OH, wherein R is alkylene, especially lower alkylene (for example in methylene, ethylene or propylene).
- a hydroxyalkyl group may be either linear or branched, such as 1-hydroxyisopropyl.
- Ischemia refers to a low oxygen state of a cell or tissue usually due to obstruction of the arterial blood supply or inadequate blood flow leading to hypoxia.
- causes of ischemia include, but are not limited to, vasoconstriction or blockage of a blood vessel.
- An “ischemic event” is a discrete occurrence producing ischemia, such as a thrombosis, cardiac arrhythmia, or myocardial infarction.
- lower alkyl refers to a cyclic, branched or straight chain monovalent alkyl radical of one to five carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl (or 2-methylpropyl), sec-butyl, n-pentyl, cyclopropylmethyl, i-amyl, n-amyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl. Lower alkyl groups can be unsubstituted or substituted. One specific example of a substituted alkyl is 1,1-dimethyl propyl.
- lower alkenyl refers to a straight or branched chain alkyl radical containing from 2 to 6 carbon atoms and also having one carbon-carbon double bond including, but not limited to, vinyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, and 5-hexenyl.
- a “mammal” includes both human and non-human mammals.
- N-protecting group or “N-protected” refers to those chemical groups intended to protect the N-terminus of an amino acid or peptide, or to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, Protective Groups In Organic Synthesis (John Wiley & Sons, New York (1981)).
- N-protecting groups include: acyl groups, such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, ⁇ -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, and 4-nitrobenzoyl; sulfonyl groups, such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forming groups, such as benzyloxycarbonyl (Cbz), p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-brom
- O-protecting group refers to a substituent which protects hydroxyl groups against undesirable reactions during synthetic procedures, such as those O-protecting groups disclosed in Greene, Protective Groups In Organic Synthesis (John Wiley & Sons, New York (1981)).
- a “pharmaceutical agent,” “pharmaceutical composition,” or “drug” refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
- the pharmaceutically acceptable salts of the compounds disclosed herein include, but are not limited to, those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
- These salts may be prepared by standard procedures, for example by reacting the free acid with a suitable organic or inorganic base. Any compound disclosed herein may alternatively be
- phenyl refers to a phenyl group, which may be unsubstituted or substituted with a substituent selected from lower alkyl, alkoxy, thioalkoxy, hydroxy and halo.
- phenylalkyl refers to a phenyl group appended to a lower alkyl radical including, but not limited to, benzyl, 4-hydroxybenzyl, 4-chlorobenzyl, and 1-naphthylmethyl.
- prodrug refers to a compound that is converted within the body to a more active form that has medicinal or therapeutic effects.
- stable compound refers to a compound that is sufficiently stable to survive isolation to a useful degree of purity from a reaction mixture and formulation into a therapeutic dosage form suitable for administration.
- subject includes both human and veterinary subjects such as primates, canines, felines, and rodents.
- terapéuticaally effective amount refers to an amount or dose sufficient to inhibit the enzymatic activity of a calpain and is capable of relieving symptoms associated with calpain activation.
- thioalkoxyalkyl refers to a thioalkoxy group appended to a lower alkyl radical.
- All chemical compounds include both the (+) and ( ⁇ ) stereoisomers, as well as either the (+) or ( ⁇ ) stereoisomer.
- HIV protease inhibitors may be divided into five general classes:
- HIV protease inhibitors are listed in Table 1.
- HIV protease inhibitor includes analogs of compounds disclosed herein (such as ritonavir and related compounds disclosed in U.S. Pat. No. 5,541,206; saquinavir and related compounds disclosed in U.S. Pat. No. 5,196,438; indinavir and related compounds disclosed in U.S. Pat. No. 5,413,999; nelfinavir and related compounds disclosed in U.S. Pat. No. 5,484,926; and amprenavir and related compounds disclosed in WO 98/56781).
- Analogs of HIV protease inhibitors include those compounds that inhibit calpain activity, regardless of their activities against HIV protease.
- HIV protease inhibitor analog describes a class of compounds, and does not provide a functional limitation on any compound described herein. TABLE 1 Representative HIV protease Inhibitors Ritonavir Saquinavir Indinavir Nelfinavir VX-478 XM-323 Amprenavir
- Ritonavir and related compounds include compounds of the formula:
- R 1 is monosubstituted thiazolyl, monosubstituted oxazolyl, monosubstituted isoxazolyl, or monosubstituted isothiazolyl; and wherein the substituent is selected from: lower alkyl; lower alkenyl; cycloalkyl; cycloalkylalkyl; cycloalkenyl; cycloalkenylalkyl; heterocyclic, wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl; and wherein the heterocyclic is unsubstituted or substituted with
- n 1, 2 or 3;
- R 2 is hydrogen or a lower alkyl
- R 3 is lower alkyl
- R 4 and R 5 are independently selected from phenyl, thiazolyl, and oxazolyl, wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy, or thioalkoxy;
- R 6 is hydrogen or lower alkyl
- R 7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl, wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with lower alkyl;
- X is hydrogen and Y is —OH, or X is —OH and Y is hydrogen, with the proviso that X is hydrogen and Y is —OH when Z is —N(R 8 )— and R 7 is unsubstituted; and with the proviso that X is hydrogen and Y is —OH when R 3 is methyl and R 7 is unsubstituted; and
- Z is absent, —O—, —S—, —CH 2 — or —N(R 8 )— wherein R 8 is a lower alkyl, cycloalkyl, —OH or —NHR 9 , wherein R 9 is hydrogen, lower alkyl, or an N-protecting group.
- Ritonavir specifically, is chemically designated as 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*10R*11R*)], has a molecular formula of C 37 H 48 N 6 O 5 S 2 , and can be represented by structural formula presented in Table 1.
- Ritonavir is available from Abbott Laboratories, Inc., under the product name NORVIR.®
- Saquinavir and related compounds include compounds of the formula:
- R is benzyloxycarbonyl or 2-quinolylcarbonyl.
- Saquinavir and related compounds may have stereochemical conformations according to the formula:
- R is benzyloxycarbonyl or 2-quinolylcarbonyl.
- Saquinavir specifically, is chemically designated as N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide with a molecular formula C 38 H 50 N 6 O 5 , and can be represented by structural formula presented in Table 1.
- Saquinavir is available from Roche Laboratories, under the product name FORTOVASE.®
- Indinavir is chemically designated as [1(1S,2R),5(S)]-2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-[2-[[(1,1-dimethylethyl)amino]carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide sulfate (1:1) salt, with a molecular formula C 36 H 47 N 5 O 4 .H 2 SO 4 , and can be represented by the structural formula presented in Table 1.
- Indinavir can be purchased from Merck & Co., Inc., as CRIXIVAN.®
- Nelfinavir is chemically designated as [3S-[2(2S *,3 s*),3 ⁇ 4a ⁇ 8a ⁇ ]]-N-(1,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide.
- the structural formula of nelfinavir is presented in Table 1, and is commercially available from Agouron Pharmaceuticals, Inc., under the product name VIRACEPT.®
- amprenavir and related compounds are disclosed in Glaxo Group Limited's PCT application WO 98/56781, herein incorporated by reference.
- Amprenavir is chemically designated as [3S-[3R*(1R*,2S*)]]-[3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester.
- Amprenavir can be represented by the structural formula presented in Table 1, and may be purchased from Glaxo Wellcome, Inc., under the product name AGERNASE.®
- Calpain can be inhibited by contacting at least one calpain with an effective amount of an HIV protease inhibitor, an analog, or other compound disclosed herein, including compounds that inhibit calpain even if HIV protease inhibition is reduced or lacking.
- an HIV protease inhibitor an analog, or other compound disclosed herein, including compounds that inhibit calpain even if HIV protease inhibition is reduced or lacking.
- These methods may be carried out in vivo or in vitro with cells, tissues, or whole animals; with one or more calpains; and with one or more HIV protease inhibitors, analogs, or related compounds disclosed herein. Additionally, these methods may employ a disclosed compound in combination with another therapeutic agent, such as another calpain inhibitor.
- a subject at risk of suffering calpain-mediated physiological damage is first identified and then provided with a calpain inhibitor, such as an HIV protease inhibitor.
- Identification of an at-risk subject can include diagnosing a subject with a condition associated with calpain induced physiological damage. For example, as a prophylactic measure, a human subject demonstrating signs of an impending stroke may be administered a calpain inhibitor (such as an HIV protease inhibitor) disclosed herein.
- Identification of an at-risk subject can also include choosing an individual research subject for experimental purposes. For example, a rat or dog may be selected to receive treatment intended to induce a stroke and then administered a calpain inhibitor disclosed herein.
- an HIV protease inhibitor, analog, or related compound is administered to a subject following an actual event implicating activation of calpain, thus putting the subject at risk of suffering calpain-mediated physiological damage.
- a human subject who recently suffered a cardiovascular ischemic event e.g., heart attack or stroke
- a composition is administered within several hours of the event precipitating calpain mediated pathologies.
- calpain-mediated physiological damage is treated by providing to a subject a therapeutically effective amount of a pharmaceutical composition.
- the pharmaceutical composition may include one or more of the calpain inhibitors disclosed herein; pharmaceutically compatible carriers, agents, counterions, adjuvants, or vehicles; another calpain inhibitor (in addition to the calpain inhibitors disclosed herein); or combinations thereof.
- subjects can be selected using more specific criteria, such as a definitive diagnosis of a particular disease or condition associated with calpain-activation (e.g., angina, cataract, myocardial infarction, stroke), or recognition of calcium activation of calpain within the subject.
- a definitive diagnosis of a particular disease or condition associated with calpain-activation e.g., angina, cataract, myocardial infarction, stroke
- recognition of calcium activation of calpain within the subject e.g., a definitive diagnosis of a particular disease or condition associated with calpain-activation (e.g., angina, cataract, myocardial infarction, stroke), or recognition of calcium activation of calpain within the subject.
- Providing a pharmaceutical composition to a subject includes methods of administering that composition.
- Routes of administration include, but are not limited to, oral and parenteral routes, such as intravenous (IV), intraperitoneal (IP), rectal, topical, ophthalmic, nasal, and transdermal.
- IV intravenous
- IP intraperitoneal
- the pharmaceutical compositions are generally provided or administered in the form of a unit dose in solid, semi-solid, or liquid dosage forms such as tablets, pills, powders, liquid solutions, or liquid suspensions.
- the drugs also may be administered intravenously in any conventional medium for intravenous injection, such as an aqueous saline medium, or in a blood plasma medium.
- the medium also may contain conventional pharmaceutical adjunct materials, such as pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers (e.g., cyclodextrins), proteins (e.g., serum albumin), hydrophilic agents (e.g., methyl cellulose), detergents, buffers, preservatives and the like.
- lipid carriers e.g., cyclodextrins
- proteins e.g., serum albumin
- hydrophilic agents e.g., methyl cellulose
- detergents e.g., methyl cellulose
- the effective amount provides an inhibition constant, for inhibition of calpain, less than or equal to about 11 ⁇ M under the following conditions: (1) using supernatant extracted from PC12 cells, (2) using N-succinyl-leu-ter 7-amino-4-methylcoumarin as the substrate for calpain activity, with (3) fluorescence measured with a 380 nm excitation filter and 480 nm emission filter, and (4) inhibition determined using enzyme kinetic equations solved using linear regression.
- Example #1 Reitonavir Inhibition.
- the therapeutically effective amounts of compounds disclosed herein also may be measured in comparison to other calpain inhibitors.
- ritonavir inhibits calpain about 20 times more effectively than the orally bioavailable calpain inhibitor, PD150606.
- certain embodiments can be distinguished from methods of treating chronic HIV infection.
- the treatment of the present invention can be given to a person who does not need a protease inhibitor, for example someone who is not infected with HIV.
- patients suffering chronic HIV infections who take HIV protease inhibitors generally follow a prolonged treatment regimen.
- the recommended dosage for NORVIR®, an orally administered ritonavir solution produced by Abbott Laboratories, North Chicago, Ill. is 600 mg b.i.d. and, if used in combination with saquinavir, an optimum dosage of 400 to 600 mg b.i.d.
- the recommended dosage for INVIRASE® an orally administered saquinavir mesylate capsule produced by Roche Laboratories, Inc., Nutley, N.J., is 600 mg t.i.d., taken in combination with a nucleoside analog. Since HIV disease is not yet curable, HIV-positive persons taking these HIV protease inhibitors must follow a prolonged, often life-long, course of daily antiviral therapy.
- therapeutically effective doses of the calpain inhibitors disclosed herein can be provided to a subject for a much shorter period of time. This period of time may be measured after a diagnosis that the subject is at risk for calpain-mediated physiological damage, or after a particular ischemic event, such as a cardiovascular ischemic event.
- the duration of treatment may be, for example, less than about a month, two weeks, one week, or even less than about 72 hours.
- a patient suffering a stroke can be provided a therapeutically effective dose of an HIV protease inhibitor for about 72 hours or less.
- the therapeutically effective dosage may be provided for a period of time from about 6 to about 72 hours.
- the duration of therapy with the calpain inhibitors disclosed herein can also be prolonged, for example, in the treatment of chronic angina or recurrent transient ischemic attacks (TIA's).
- administration can be repeated, but intermittent (for example, following an episode of angina or TIA), even though intermittent or episodic administration would be avoided in an antiviral treatment because it could lead to the development of viral drug resistance.
- the specific dose level, frequency of dosage, and duration of treatment for any particular subject may be varied and will depend upon a variety of factors, including: the activity of the specific pharmaceutical composition; the metabolic stability and length of action of that composition; the age, body weight, general health, gender, diet, and other characteristics of the subject; mode and time of administration; the rate of excretion; drug combination parameters; and severity of the condition of the subject undergoing treatment.
- compositions can be used in the treatment of a variety of conditions or diseases associated with calpain activation, including conditions or diseases caused by or mediated by enzymatically active calpains.
- conditions or diseases associated with calpain-mediated physiological damage include, but are not limited to, neurological conditions such as cerebral trauma, spinal cord trauma, subarachnoid hemmorrhage, Alzheimer's disease, alcohol-induced brain damage, muscular dystrophy; as well as non-neurological conditions, such as cataract, coronary atherosclerosis, restenosis, and arthritis.
- Post-ischemic calpain activation also may be associated with a cardiovascular ischemic event such as, for example, myocardial infarction, angina, cardiac trauma, arhythmia, stroke, thrombosis, or thrombotic platelet aggregation.
- a cardiovascular ischemic event such as, for example, myocardial infarction, angina, cardiac trauma, arhythmia, stroke, thrombosis, or thrombotic platelet aggregation.
- the trauma or condition leading to the calpain-mediated physiological damage may be induced or accidental.
- ritonavir was unexpectedly found to competitively inhibit calpain with an inhibition constant of about 11 ⁇ M.
- PC12 cells were grown in an RPMI solution containing 5% fetal bovine serum, 10% heat-inactivated horse serum, and 50 mg/L gentamicin. Cells were isolated by centrifugation, and cell pellets suspended in 1 mL of extract buffer, containing 30 mM TRIS at pH 6.8, 15 mMEDTA, 5 mMEGTA, 1 mMDTT, 0.5 M PMSF, 0.1 mg/mL AEBSF, 14.4 mM 2-mercaptoethanol, and 1% triton x-100. After 1 cycle of freeze-thaw, the cell extract was centrifuged at 4° C. at 14,000 g for 20 minutes. The supernatant was removed and assayed.
- extract buffer containing 30 mM TRIS at pH 6.8, 15 mMEDTA, 5 mMEGTA, 1 mMDTT, 0.5 M PMSF, 0.1 mg/mL AEBSF, 14.4 mM 2-mercaptoethanol, and 1% triton x-100. After
- Calpain activity was measuring using N-succinyl-leu-tyr 7-amino-4-methylcoumarin as the specific peptide substrate. Fluorescence was measured in a 96-well microplate format (Dyrex Technologies (UK), Middlesex) with a 380 nm excitation filter and 480 nm emission filter. Total volume for each well was 300 ⁇ L containing Hanks' Balanced Salt Solution 1 ⁇ (Cellgro), 2 ⁇ M calcium chloride, and varying amounts of inhibitor and N-succinyl-ley-tyr-7-amino-4-methylcoumarin.
- v i is the velocity in the presence of inhibitor
- v m is the velocity in absence of inhibitor
- K a Michaelis-Menten constant
- K i in Formula (6) is the dissociation constant for the enzyme-substrate-inhibitor complex.
- K ia is the dissociation constant of the enzyme-substrate complex and K ii is the dissociation constant of the enzyme-substrate-inhibitor complex.
- Calpain specific activity was obtained by subtracting the rate obtained in the presence of calcium from the rated obtained in the absence of calcium. In these cell extracts, the observed kinetic parameters represent aggregate estimates since both calpain isoforms were present.
- ritonavir was unexpectedly found to increase survival of hippocampal primary neurons exposed to 4-hydroxynonenal (HNE) induced oxidative stress.
- Hippocampal primary neuron cell cultures were prepared according to the methods described by Mattson, et al., Methods Cell Biol., 46:187-216 (1995). Hippocampi were obtained from rat embryos and incubated for 15 minutes in a solution of 2 mg/ml trypsin in Hank's Balanced Salt Solution (HBSS) containing 2.4 g/l N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid] (HEPES) and 10 mg/l gentamicin, pH 7.2 at a concentration of 2 hippocampi/ml. The hippocampi were then rinsed three times in 10 ml of HBSS and incubated for 5 min. in a solution of 1 mg trypsin inhibitor/ml of HBSS. Finally, the cells were rinsed three times with 10 ml of HBSS.
- HBSS Hank's Balanced Salt Solution
- Ritonavir was assayed at the following concentrations: 1 pM, 10 pM, 100 pM, 1 nM, and 10 nM in Locke's solution. The final concentration of HNE was 1 mM. The effect of ritonavir alone on hippocampal neuron survival was examined at the each of the above concentrations. The cytoprotective effect of ritonavir also was evaluated in combination with 1 mM HNE. For the combination of ritonavir and HNE, the culture was pre-treated with ritonavir at least 15 min. prior to adding HNE solution. The control cultures without ritonavir or HNE were treated with Locke's solution containing 10 nM of DMSO to match the DMSO content in ritonavir-treated cultures. Four dishes were examined for each of the groups.
- Each of the cultures was photographed with phase-contrast inverted Zeiss microscope attached with a 35 mm camera at pre-treatment, 24 hours, and 48 hours after treatment at the same location marked by a scratched grid on the bottom of culture dish. Two photos were taken from each of the dishes. Neuronal survival was quantified by counting the number of neurons on each of the photos. Neuronal viability was identified and determined by morphological criteria: viable neurons had phase-bright somas and intact processes while nonviable neurons had phase-dark, vacuolated somas, and fragmented neuritis. The survival rate was calculated for each of the dishes by using the number of surviving neurons at the 24 hour or 48 hour time point divided by the number of surviving neurons at pre-treatment from the same dish.
- Hippocampal primary neurons maintained in Locke's solution showed a slight time-dependent decrease in survival.
- Ritonavir alone in culture medium induced concentration-dependent effects on neuronal survival. At lower concentrations of 1-100 pM, ritonavir itself had no effect on cell survival as compared to control cells. At higher concentrations of 1 nM, and particularly 10 nM, ritonavir significantly reduced neuronal survival (p ⁇ 0.05 as compared to control, ritonavir 1 pM, ritonavir 10 pM, ritonavir 100 pM, and ritonavir 100 pM+HNE).
- ritonavir was strongly cytoprotective in HNE-treated hippocampal primary neurons.
- the cytoprotection was dose-dependent, as ritonavir at low concentrations of 1 pM exhibited no cytoprotective activity against HNE-induced cytotoxicity.
- concentrations of 10 pM cytoprotective activity emerged, which increased up to concentrations of 100 pM, where the drug significantly protected hippocampal primary neurons against HNE-induced cytotoxicity (p ⁇ 0.05 as compared to HNE, ritonavir 1 pM+HNE, and ritonavir 10 pM+HNE).
- the level of cytoprotection was 100% at this dose level—there was no difference between the ritonavir 100 pM+HNE and the control group in cell survival measures.
- ritonavir At doses higher than 100 pM, ritonavir exhibited cytotoxicity, since neuronal survival in both ritonavir 1 nM+HNE and ritonavir 10 nM+HNE was significantly lower than in the control, ritonavir 100 pM+HNE, and ritonavir 1-100 pM groups (p ⁇ 0.05). Exposure to 10 ⁇ M ritonavir resulted in essentially 100% cell death after 24 hours.
- Spectrin is a specific substrate of calpains and spectrin breakdown has been shown to be associated with neuronal injury, such as after trauma or NMDA-induced neuronal cell injury.
- spectrin was used to assay calpain activity in the presence of ritonavir.
- This example illustrates how compounds disclosed herein may be screened for therapeutic effectiveness.
- ritonavir is used to treat neuronal damage in rats following induced strokes.
- Group I receives no treatment.
- Group II is cannulated to induce a stroke, as described below, and orally administered ritonavir.
- Group III is cannulated, but receives no drug treatment, and
- Group IV is not cannulated, but is administered ritonavir.
- the number of animals provides an error alpha of 0.05 and a beta (power) of 0.80 with an expected treatment effect size of approximately 1.00.
- the largest difference in the mean area of brain injury is found between the two treatments incorporating surgery and, expressed in standard deviation units, is equal to [mean1 ⁇ mean2]/(standard deviation units) ⁇ 1.00 (calculations performed according to Cohen, Statistical Power Analysis for the Behavioral Sciences, 2 nd edition (Lawrence Erlbaum Assoc. 1988)).
- Drug doses are determined according to the expected blood level of ritonavir after oral administration and the ritonavir K i . To minimize Type II error rates, ritonavir is administered at a higher normalized dose compared to human dosage recommendations.
- Ritonavir (15 mg/kg) is orally administered to the rats two hours before the surgical procedure begins, and 10% chloral hydrate (300 mg/kg) is used for anesthesia.
- the carotid arteries (including the common, external, and internal artery) are surgically exposed, and a siliconized nylon thread is inserted via needle catheter through the external artery into the middle cerebral artery to occlude blood flow in this artery. The thread is left in place for 60 minutes, then withdrawn and the skin sutured.
- An artery occlusion time of 60 minutes initiates reproducible brain tissue injury and mimics stroke injury, where reperfusion can sometimes occur spontaneously or by interventional procedures within an hour.
- Drug administration continues every 8 hours for three days, for a total of 9 doses. Prior to the last dose, a blood sample of 0.5 mL is obtained from the tail vein of each rat and analyzed for drug concentration.
- tissue samples are analyzed for differences in brain injury among the four treatment groups.
- calpain inhibitors to be tested in accordance with the assays of Examples 1-3 include, but are not limited to, compounds disclosed in U.S. Pat. Nos. 5,541,206 and 5,413,999, such as the following:
- ritonavir For the treatment of angina or a transient ischemic attack, 300-600 mg of ritonavir are administered twice a day beginning the day of an attack, continued for 72 hours, and then stopped until the next attack occurs.
- a compound disclosed herein is administered following initial clinical presentation with signs and symptoms of an MI (such as chest pain and EKG changes), or following laboratory confirmation of the MI (such as presence of elevated cardiac enzyme levels such as CPK-MB). Administration would be continued for at least a week, for example, a month, or in some examples, no more than one or two weeks. Repeated courses of the calpain inhibitor can be given for subsequent MI's or other calpain mediated conditions (such as an ischemic or hemorrhagic stroke).
- treatment may be sustained (for example, 100-300 mg by mouth each day, for example as a single dose) for life, or until extraction of a cataractous crystalline lens.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional application No. 60/202,378, filed on May 4, 2000, herein incorporated by reference.
- This invention relates to enzymatic inhibitors, particularly calpain inhibitors, and more particularly, calpain inhibition by HIV protease inhibitors.
- Calpains are mammalian calcium-dependent neutral cysteine proteases involved in programmed cell death (apoptosis). Calpains are referred to as cysteine proteases because they include a cysteine residue that plays a critical role in the catalytic process. In the presence of calcium, a cysteine protease catalytic triad forms when three amino acid residues (Cys105, His262, and Asn 286) are brought together in the active site.
- Two major classes of calpains are known, μ-calpain and m-calpain, which differ in their sensitivities toward calcium. Some tissue-specific forms of calpain also have been identified. Substrates of calpain include cellular proteins such as cytoskeletal proteins, membrane-bound receptors, calmodulin binding proteins, myofibrillar proteins, enzymes, and transcription factors.
- Calpain can become activated under ischemic conditions. It has been proposed that ischemia overactivates cellular membrane receptors, which causes an influx of calcium ions into the cell. This influx activates calcium-dependent enzymes, including calpains, and the calpains begin digesting cellular proteins, which contributes to cell death.
- Inhibition of calpain has provided therapeutic possibilities for a number of different diseases, including cerebral ischemia (particularly strokes), traumatic brain injury, subarachnoid hemorrhage, chronic neurodegeneration (e.g., Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis), Alzheimer's disease, cardiac ischemia (particularly myocardial infarction), muscular dystrophy, cataracts, thrombotic platelet aggregation, restenosis, and joint inflammation (particularly arthritis).
- A more detailed overview of calpains and calpain inhibitors can be found in Wang, et al.,Advances in Pharmacology, 37:117-52 (1997). Patents disclosing calpain inhibitors include: Zimmerman, et al., U.S. Pat. No. 5,374,623; Wang, et al., U.S. Pat. No. 5,760,048; Munoz, et al., U.S. Pat. No. 5,872,101; Munoz, et al., U.S. Pat. No. 5,969,100; and Spruce, et al., U.S. Pat. No. 6,004,933.
- The human immunodeficiency virus (HIV) is a retrovirus that causes immunosuppression in humans and leads to a disease complex known as acquired immunodeficiency syndrome (AIDS). HIV protease is an aspartyl protease that plays a central role in viral processing by cleaving the HIV GAG and GAG-POL polypeptides to produce mature viral core proteins and virus-specific enzymes. The HIV protease is called an aspartyl protease due to an important aspartyl residue in the active site that hydrolyzes the peptide bond of its substrate. Coffin et al.,Retroviruses (Cold Spring Harbor Laboratory Press, 1997), provides a more detailed explanation of HIV protease.
- Commercially available HIV protease inhibitors include ritonavir, saquinavir, indinavir, nelfinavir, and amprenavir. Numerous other HIV protease inhibitors are currently being tested in humans, but have not yet been approved by the United States Food and Drug Administration (FDA) for use against HIV, including ABT378, BMS232632, DMP450, GW433908, L-756,423, and timpranavir. Other HIV protease inhibitors have been disclosed in the patent literature, including: Martin et al., U.S. Pat. No. 5,196,438; Vacca et al., U.S. Pat. No. 5,413,999; Dressman et al., U.S. Pat. No. 5,484,926; Kempf et al., U.S. Pat. No. 5,541,206; WO 97/0139 and WO 00/04016 by Abbott Laboratories; and WO 98/56781 by Glaxo Group Limited.
- A variety of calpain inhibitors are disclosed, as well as methods of using these inhibitors to treat conditions associated with calpain activation. In some embodiments, HIV inhibitors are used to inhibit calpain activity. In other embodiments, the calpain inhibitor is an analog of or compound related to an HIV protease inhibitor.
- A calpain may be inhibited by contacting the calpain with a disclosed inhibitor, such as an HIV protease inhibitor, analog, or related compound. In some embodiments, the calpain inhibitor is administered in therapeutically effective amounts to inhibit calpains within cells of subjects. In other embodiments, the calpain inhibitor is a compound having one or more of the following structures or clinical names, without reference to the ability of that compound to inhibit HIV protease activity:
-
- wherein R1 is monosubstituted thiazolyl, mono substituted oxazolyl, monosubstituted isoxazolyl, or monosubstituted isothiazolyl; and wherein the substituent is selected from: lower alkyl; lower alkenyl; cycloalkyl; cycloalkylalkyl; cycloalkenyl; cycloalkenylalkyl; heterocyclic, wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy, and thioalkoxy; (heterocyclic)alkyl, wherein the heterocyclic is defined as above; alkoxyalkyl; thioalkoxyalkyl; alkylamino; dialkylamino; phenyl, wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy and thioalkoxy; phenylalkyl, wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy and thioalkoxy; dialkylaminoalkyl; alkoxy; and thioalkoxy;
- n is 1, 2 or 3;
- R2 is hydrogen or a lower alkyl;
- R3 is a lower alkyl;
- R4 and R5 are independently selected from phenyl, thiazolyl, and oxazolyl, wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy, and thioalkoxy;
- R6 is hydrogen or lower alkyl;
- R7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl, wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with lower alkyl;
- X is hydrogen and Y is —OH, or X is —OH and Y is hydrogen, with the proviso that X is hydrogen and Y is —OH when Z is —N(R8)— and R7 is unsubstituted, and with the proviso that X is hydrogen and Y is —OH when R3 is methyl and R7 is unsubstituted; and
- Z is absent, 'O—, 'S—, —CH2— or —N(R8)— wherein R8 is a lower alkyl, cycloalkyl, —OH or —NHR9, wherein R9 is hydrogen, lower alkyl or an N-protecting group; or
-
- wherein R is benzyloxycarbonyl or 2-quinolylcarbonyl; or,
- (3) any of: ritonavir; saquinavir; indinavir; nelfinavir; or amprenavir.
- Subjects at risk of suffering calpain-mediated physiological damage may be identified and administered an HIV protease inhibitor, or another compound disclosed herein, following an event associated with activation of calpain, such as ischemia in the cardiovascular (including the neurovascular) system, or the myocardial or neural tissues which these systems perfuse.
- Some embodiments include treating or preventing calpain-mediated physiological damage in a subject. In these embodiments, calpain-mediated physiological damage is treated by administering to a subject a therapeutically effective amount of a pharmaceutical composition having at least one protease inhibitor. Particular examples of pharmaceutical compositions include those with plural HIV protease inhibitors; pharmaceutically compatible carriers, agents, counterions, adjuvants, or vehicles; and/or other calpain inhibitors (in addition to the compounds disclosed herein). Treatments may be prophylactic or reparative.
- Particular examples of therapeutically effective amounts of compounds include amounts that provide an inhibition constant, Ki, for inhibition of calpain less than or equal to about 11 μM. Additionally, therapeutically effective doses of compounds may be administered to a subject for a limited period of time, such as about a month, a week, or even less than about 72 hours.
- The pharmaceutical compositions can be used to treat a variety of conditions or diseases associated with calpain activation, including cardiovascular diseases. In particular embodiments, the treated condition is ischemia, such as myocardial or neural ischemia, resulting from decreased oxygenation of these tissues, as may occur in myocardial infarction, coronary stenosis or vasospasm, cerebrovascular accidents, such as ischemic or hemorrhagic stroke, and neurological trauma.
- An “animal” is a living multicellular vertebrate organism, a category which includes, for example, mammals and birds.
- The article “a” or “an” includes both the singular or plural, unless the context of its use clearly indicates otherwise.
- The term “amino” refers to a chemical functionality —NR1R2 where R1 and R2 are independently hydrogen, alkyl, or aryl.
- The term “activated ester derivative” refers to acid halides, such as acid chlorides, and activated esters including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides (such as isobutyloxycarbonylchloride), N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters, N-hydroxy-5-norbornene-2,3-dicarboxamide derived esters, and 2,4,5-trichlorophenol derived esters and the like.
- An “analog” is a molecule that is structurally similar to another molecule but which differs slightly in chemical structure from a parent compound, for example by the replacement of one atom by an atom of a different element, or by the substitution of one functional group for another. Examples include, but are not limited to, a homolog (which differs by an increment in the chemical structure, such as a difference in the length of an alkyl chain), a molecular fragment, a structure that differs by one or more functional groups, or a change in ionization. Structural analogs are often found using quantitative structure activity relationships (QSAR), with techniques such as those disclosed inRemington: The Science and Practice of Pharmacology, 19th Edition (1995), chapter 28. A derivative is a biologically active molecule derived from the base molecular structure. A mimetic is a biomolecule that mimics the activity of another biologically active molecule. Biologically active molecules can include both chemical structures and peptides that mimic the calpain inhibition activities of the compounds disclosed herein, regardless of whether they also inhibit HIV protease activity.
- The term “alkylamino” refers to a lower alkyl radical appended to an —NH radical.
- The term “alkoxy” refers to a substituted or unsubstituted alkoxy, where an alkoxy has the structure —O—R, where R is a substituted or unsubstituted alkyl. In an unsubstituted alkoxy, the R is an unsubstituted alkyl. The term “substituted alkoxy” refers to a group having the structure —O—R, where R is alkyl which is substituted with a non-interfering substituent. “Lower alkoxy” refers to any alkoxy in which R is a lower alkyl. “Thioalkoxy” refers to —S—R, where R is substituted or unsubstituted alkyl.
- The term “alkoxyalkyl” refers to an alkoxy group appended to a lower alkyl radical.
- The term “alkyl” refers to a cyclic, branched, or straight chain alkyl group containing only carbon and hydrogen, which, unless otherwise described, contains one to twelve carbon atoms. This term is further exemplified by groups such as methyl, ethyl, n-propyl, isobutyl, t-butyl, pentyl, pivalyl, heptyl, adamantyl, and cyclopentyl. Alkyl groups can be unsubstituted or substituted with one or more substituents, for example halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
- The term “aryl” refers to a monovalent unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl), which can optionally be unsubstituted or substituted with, for example, halogen, alkyl, alkoxy, mercapto (—SH), alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality.
- “Calpain mediated physiological damage” refers to pathological conditions mediated by calpain. Such conditions can include a variety of ischemic events (such as myocardial or cerebral ischemia), as well as non-ischemic disorders (such as Alzheimer's disease or muscular dystrophy).
- “Carbonyl containing group” refers to any substituent containing a carbon-oxygen double bond, including substituents based on —COR where R is an alkyl, lower alkyl, hydroxyl, or a secondary, tertiary, or quaternary amine. The term also encompasses oximes and hydrazones. Alternatively, “carbonyl-containing group” refers to —R1COR2 groups wherein R2 is alkyl, lower alkyl, hydroxyl, or secondary, tertiary, or quaternary amine and R1 is alkylene, such as methylene (—CH2—). Examples include —COOH, —CH2COOH, —CH2COOCH3, —CH2CONH2, and —CH2CON(CH3)2.
- “Carboxyl” refers to the radical —COOH, and substituted carboxyl refers to —COR where R is alkyl, lower alkyl or a carboxylic acid or ester.
- The term “cycloalkyl” refers to an aliphatic ring having 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.
- The term “cycloalkylalkyl” refers to a cycloalkyl group appended to a lower alkyl radical, including, but not limited to, cyclohexylmethyl.
- The term “cycloalkenyl” refers to an aliphatic ring having 5 to 7 carbon atoms and also having one carbon-carbon double bond including, but not limited to, cyclopentenyl and cyclohexenyl.
- The term “cycloalkenyalkyl” refers to a cycloalkenyl group appended to a lower alkyl radical including, but not limited to, cyclopentenylmethyl and cyclohexenylmethyl.
- The term “dialkylamino” refers to —N—R1—R2 wherein R1 and R2 are independently selected from lower alkyl groups.
- The term “dialkylaminoalkyl” refers to —N—R1—R2, which is appended to a lower alkyl radical, wherein R1 and R2 are independently selected from lower alkyl groups.
- The term “halo” or refers to fluoro, bromo, chloro and iodo substituents. The term “halogen” refers to fluorine, bromine, chlorine, and iodine.
- A “heart attack” is a general term encompassing cardiac traumas or diseases, such as myocardial infarction, angina, or cardiac arrhythmia. It is often, but not invariable, the result of cardiovascular disease, such as that seen in atherosclerosis.
- The term “heterocycle” (or “heterocyclic”) refers to a monovalent saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g. benzyl, morpholino, pyridyl, or furyl), or multiple condensed rings (e.g. naphthyl, quinolinyl, indolizinyl or benzo[b]thienyl), and having at least one heteroatom, (defined as N, O, P, or S) within the ring. A heterocycle can optionally be unsubstituted or substituted with, for example, halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, or other functionality. Examples include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl.
- The term “(heterocyclic)alkyl” as used herein refers to a heterocyclic group appended to a lower alkyl radical including, but not limited to, pyrrolidinylmethyl and morpholinylmethyl.
- “HIV disease” refers to a well recognized constellation of signs and symptoms (including the development of opportunistic infections) in persons who are infected by a human immunodeficiency virus (HIV), as determined by antibody or western blot studies. Laboratory findings associated with this disease are a progressive decline in T-helper cells.
- “HIV protease inhibitor” refers to compounds which inhibit the enzymatic activity of an HIV protease. Examples include, but are not limited to, the HIV protease inhibitors disclosed in Table 1.
- “Hydroxyl” (or “hydroxy”) refers to —OH. “Hydroxyalkyl” refers to —R—OH, wherein R is alkylene, especially lower alkylene (for example in methylene, ethylene or propylene). A hydroxyalkyl group may be either linear or branched, such as 1-hydroxyisopropyl.
- “Ischemia” refers to a low oxygen state of a cell or tissue usually due to obstruction of the arterial blood supply or inadequate blood flow leading to hypoxia. Causes of ischemia include, but are not limited to, vasoconstriction or blockage of a blood vessel. An “ischemic event” is a discrete occurrence producing ischemia, such as a thrombosis, cardiac arrhythmia, or myocardial infarction.
- The term “lower alkyl” refers to a cyclic, branched or straight chain monovalent alkyl radical of one to five carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl (or 2-methylpropyl), sec-butyl, n-pentyl, cyclopropylmethyl, i-amyl, n-amyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl. Lower alkyl groups can be unsubstituted or substituted. One specific example of a substituted alkyl is 1,1-dimethyl propyl.
- The term “lower alkenyl” refers to a straight or branched chain alkyl radical containing from 2 to 6 carbon atoms and also having one carbon-carbon double bond including, but not limited to, vinyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, and 5-hexenyl.
- A “mammal” includes both human and non-human mammals.
- The term “N-protecting group” or “N-protected” refers to those chemical groups intended to protect the N-terminus of an amino acid or peptide, or to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene,Protective Groups In Organic Synthesis (John Wiley & Sons, New York (1981)). N-protecting groups include: acyl groups, such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, and 4-nitrobenzoyl; sulfonyl groups, such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forming groups, such as benzyloxycarbonyl (Cbz), p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dime thoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, and phenylthiocarbonyl; alkyl groups, such as benzyl, triphenylmethyl, and benzyloxymethyl; and silyl groups, such as trimethylsilyl.
- The term “O-protecting group” refers to a substituent which protects hydroxyl groups against undesirable reactions during synthetic procedures, such as those O-protecting groups disclosed in Greene,Protective Groups In Organic Synthesis (John Wiley & Sons, New York (1981)). O-protecting groups include: substituted methyl ethers, such as methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, t-butyl, benzyl and triphenylmethyl; tetrahydropyranyl ethers; substituted ethyl ethers, such as 2,2,2-trichloroethyl; silyl ethers, such as trimethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl; and esters prepared by reacting the hydroxyl group with a carboxylic acid, such as acetate, propionate, and benzoate.
- A “pharmaceutical agent,” “pharmaceutical composition,” or “drug” refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject. The pharmaceutically acceptable salts of the compounds disclosed herein include, but are not limited to, those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide. These salts may be prepared by standard procedures, for example by reacting the free acid with a suitable organic or inorganic base. Any compound disclosed herein may alternatively be administered as a pharmaceutically acceptable salt thereof.
- The term “phenyl” refers to a phenyl group, which may be unsubstituted or substituted with a substituent selected from lower alkyl, alkoxy, thioalkoxy, hydroxy and halo.
- The term “phenylalkyl” refers to a phenyl group appended to a lower alkyl radical including, but not limited to, benzyl, 4-hydroxybenzyl, 4-chlorobenzyl, and 1-naphthylmethyl.
- The term “prodrug” refers to a compound that is converted within the body to a more active form that has medicinal or therapeutic effects.
- The term “stable compound” refers to a compound that is sufficiently stable to survive isolation to a useful degree of purity from a reaction mixture and formulation into a therapeutic dosage form suitable for administration.
- The term “subject” includes both human and veterinary subjects such as primates, canines, felines, and rodents.
- The term “therapeutically effective amount” refers to an amount or dose sufficient to inhibit the enzymatic activity of a calpain and is capable of relieving symptoms associated with calpain activation.
- The term “thioalkoxyalkyl” refers to a thioalkoxy group appended to a lower alkyl radical.
- Other chemistry terms herein are used according to conventional usage in the art, as exemplified byThe McGraw-Hill Dictionary of Chemical Terms (1985) and The Condensed Chemical Dictionary (1981).
- All chemical compounds include both the (+) and (−) stereoisomers, as well as either the (+) or (−) stereoisomer.
- HIV protease inhibitors may be divided into five general classes:
- 1. hydroxyethylene or dihydroxyethylene isotere state analogs;
- 2. hydroxyethylamine isotere analogs;
- 3. C2 symmetry-based inhibitors;
- 4. (R)-(hydroxyethyl) urea isotere analogs; and
- 5. nonpeptide HIV protease inhibitors.
- Particular, commonly known HIV protease inhibitors are listed in Table 1.
- The term “HIV protease inhibitor” includes analogs of compounds disclosed herein (such as ritonavir and related compounds disclosed in U.S. Pat. No. 5,541,206; saquinavir and related compounds disclosed in U.S. Pat. No. 5,196,438; indinavir and related compounds disclosed in U.S. Pat. No. 5,413,999; nelfinavir and related compounds disclosed in U.S. Pat. No. 5,484,926; and amprenavir and related compounds disclosed in WO 98/56781). Analogs of HIV protease inhibitors include those compounds that inhibit calpain activity, regardless of their activities against HIV protease. Therefore, the term “HIV protease inhibitor analog” describes a class of compounds, and does not provide a functional limitation on any compound described herein.
TABLE 1 Representative HIV protease Inhibitors Ritonavir Saquinavir Indinavir Nelfinavir VX-478 XM-323 Amprenavir - The chemical structures of ritonavir and related compounds, including ritonavir analogs, are disclosed in Kempf et al.'s U.S. Pat. No. 5,541,206, herein incorporated by reference.
-
- wherein
- R1 is monosubstituted thiazolyl, monosubstituted oxazolyl, monosubstituted isoxazolyl, or monosubstituted isothiazolyl; and wherein the substituent is selected from: lower alkyl; lower alkenyl; cycloalkyl; cycloalkylalkyl; cycloalkenyl; cycloalkenylalkyl; heterocyclic, wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl; and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy, and thioalkoxy; (heterocyclic)alkyl, wherein the heterocyclic is defined as above; alkoxyalkyl; thioalkoxyalkyl; alkylamino; dialkylamino; phenyl, wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy and thioalkoxy; phenylalkyl, wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy and thioalkoxy; dialkylaminoalkyl; alkoxy; or thioalkoxy;
- n is 1, 2 or 3;
- R2 is hydrogen or a lower alkyl;
- R3 is lower alkyl;
- R4 and R5 are independently selected from phenyl, thiazolyl, and oxazolyl, wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from halo, lower alkyl, hydroxy, alkoxy, or thioalkoxy;
- R6 is hydrogen or lower alkyl;
- R7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl, wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with lower alkyl;
- X is hydrogen and Y is —OH, or X is —OH and Y is hydrogen, with the proviso that X is hydrogen and Y is —OH when Z is —N(R8)— and R7 is unsubstituted; and with the proviso that X is hydrogen and Y is —OH when R3 is methyl and R7 is unsubstituted; and
- Z is absent, —O—, —S—, —CH2— or —N(R8)— wherein R8 is a lower alkyl, cycloalkyl, —OH or —NHR9, wherein R9 is hydrogen, lower alkyl, or an N-protecting group.
- Ritonavir, specifically, is chemically designated as 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*10R*11R*)], has a molecular formula of C37H48N6O5S2, and can be represented by structural formula presented in Table 1. Ritonavir is available from Abbott Laboratories, Inc., under the product name NORVIR.®
- The chemical structures of saquinavir and related compounds, including saquinavir analogs, are disclosed in Martin et al.'s U.S. Pat. No. 5,196,438, herein incorporated by reference.
-
-
- wherein R is benzyloxycarbonyl or 2-quinolylcarbonyl.
- Saquinavir, specifically, is chemically designated as N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide with a molecular formula C38H50N6O5, and can be represented by structural formula presented in Table 1. Saquinavir is available from Roche Laboratories, under the product name FORTOVASE.®
- The chemical structures of indinavir and related compounds, including analogs, are disclosed in Vacca et al.'s U.S. Pat. No. 5,413,999, herein incorporated by reference.
- Indinavir is chemically designated as [1(1S,2R),5(S)]-2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-[2-[[(1,1-dimethylethyl)amino]carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide sulfate (1:1) salt, with a molecular formula C36H47N5O4.H2SO4, and can be represented by the structural formula presented in Table 1. Indinavir can be purchased from Merck & Co., Inc., as CRIXIVAN.®
- The chemical structures of nelfinavir, nelfinavir mesylate, and related compounds, including nelfinavir analogs, are disclosed in Dressman et al.'s U.S. Pat. No. 5,484,926, herein incorporated by reference.
- Nelfinavir is chemically designated as [3S-[2(2S *,3 s*),3α4aβ8aβ]]-N-(1,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide. The structural formula of nelfinavir is presented in Table 1, and is commercially available from Agouron Pharmaceuticals, Inc., under the product name VIRACEPT.®
- The chemical structures of amprenavir and related compounds, including amprenavir analogs, are disclosed in Glaxo Group Limited's PCT application WO 98/56781, herein incorporated by reference.
- Amprenavir is chemically designated as [3S-[3R*(1R*,2S*)]]-[3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester. Amprenavir can be represented by the structural formula presented in Table 1, and may be purchased from Glaxo Wellcome, Inc., under the product name AGERNASE.®
- Calpain can be inhibited by contacting at least one calpain with an effective amount of an HIV protease inhibitor, an analog, or other compound disclosed herein, including compounds that inhibit calpain even if HIV protease inhibition is reduced or lacking. These methods may be carried out in vivo or in vitro with cells, tissues, or whole animals; with one or more calpains; and with one or more HIV protease inhibitors, analogs, or related compounds disclosed herein. Additionally, these methods may employ a disclosed compound in combination with another therapeutic agent, such as another calpain inhibitor.
- Some embodiments involve inhibiting calpains within particular subjects. In some embodiments, a subject at risk of suffering calpain-mediated physiological damage is first identified and then provided with a calpain inhibitor, such as an HIV protease inhibitor. Identification of an at-risk subject can include diagnosing a subject with a condition associated with calpain induced physiological damage. For example, as a prophylactic measure, a human subject demonstrating signs of an impending stroke may be administered a calpain inhibitor (such as an HIV protease inhibitor) disclosed herein. Identification of an at-risk subject can also include choosing an individual research subject for experimental purposes. For example, a rat or dog may be selected to receive treatment intended to induce a stroke and then administered a calpain inhibitor disclosed herein.
- In other embodiments, an HIV protease inhibitor, analog, or related compound is administered to a subject following an actual event implicating activation of calpain, thus putting the subject at risk of suffering calpain-mediated physiological damage. For example, a human subject who recently suffered a cardiovascular ischemic event (e.g., heart attack or stroke) may be administered a therapeutically effective amount of pharmaceutical composition that includes a calpain inhibitor disclosed herein. In many embodiments, a composition is administered within several hours of the event precipitating calpain mediated pathologies.
- Other embodiments include treating or preventing calpain-mediated physiological damage in a subject animal, for example, a human. In these embodiments, calpain-mediated physiological damage is treated by providing to a subject a therapeutically effective amount of a pharmaceutical composition. The pharmaceutical composition may include one or more of the calpain inhibitors disclosed herein; pharmaceutically compatible carriers, agents, counterions, adjuvants, or vehicles; another calpain inhibitor (in addition to the calpain inhibitors disclosed herein); or combinations thereof. Although the treatment can be used prophylactically in any patient in a demographic group at risk for calpain-mediated physiological damage, subjects also may be selected using more specific criteria, such as a definitive diagnosis of a particular disease or condition associated with calpain-activation (e.g., angina, cataract, myocardial infarction, stroke), or recognition of calcium activation of calpain within the subject.
- Providing a pharmaceutical composition to a subject includes methods of administering that composition. Routes of administration include, but are not limited to, oral and parenteral routes, such as intravenous (IV), intraperitoneal (IP), rectal, topical, ophthalmic, nasal, and transdermal. If orally bioavailable HIV protease inhibitors are used, the pharmaceutical compositions are generally provided or administered in the form of a unit dose in solid, semi-solid, or liquid dosage forms such as tablets, pills, powders, liquid solutions, or liquid suspensions. However, the drugs also may be administered intravenously in any conventional medium for intravenous injection, such as an aqueous saline medium, or in a blood plasma medium. The medium also may contain conventional pharmaceutical adjunct materials, such as pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers (e.g., cyclodextrins), proteins (e.g., serum albumin), hydrophilic agents (e.g., methyl cellulose), detergents, buffers, preservatives and the like. A more complete explanation of acceptable pharmaceutical carriers can be found inRemington: The Science and Practice of Pharmacy (19th Edition, 1995) in chapter 95.
- Therapeutically effective amounts of compounds can be determined in many different ways, depending on the toxicity of the individual HIV protease inhibitor. In some embodiments, the effective amount provides an inhibition constant, for inhibition of calpain, less than or equal to about 11 μM under the following conditions: (1) using supernatant extracted from PC12 cells, (2) using N-succinyl-leu-ter 7-amino-4-methylcoumarin as the substrate for calpain activity, with (3) fluorescence measured with a 380 nm excitation filter and 480 nm emission filter, and (4) inhibition determined using enzyme kinetic equations solved using linear regression. One example determination of an effective amount under these conditions is provided below in Example #1—Ritonavir Inhibition.
- The therapeutically effective amounts of compounds disclosed herein also may be measured in comparison to other calpain inhibitors. For example, ritonavir inhibits calpain about 20 times more effectively than the orally bioavailable calpain inhibitor, PD150606.
- Additionally, certain embodiments can be distinguished from methods of treating chronic HIV infection. The treatment of the present invention can be given to a person who does not need a protease inhibitor, for example someone who is not infected with HIV. Moreover, patients suffering chronic HIV infections who take HIV protease inhibitors generally follow a prolonged treatment regimen. For example, the recommended dosage for NORVIR®, an orally administered ritonavir solution produced by Abbott Laboratories, North Chicago, Ill., is 600 mg b.i.d. and, if used in combination with saquinavir, an optimum dosage of 400 to 600 mg b.i.d. As another example, the recommended dosage for INVIRASE®, an orally administered saquinavir mesylate capsule produced by Roche Laboratories, Inc., Nutley, N.J., is 600 mg t.i.d., taken in combination with a nucleoside analog. Since HIV disease is not yet curable, HIV-positive persons taking these HIV protease inhibitors must follow a prolonged, often life-long, course of daily antiviral therapy.
- In contrast, therapeutically effective doses of the calpain inhibitors disclosed herein can be provided to a subject for a much shorter period of time. This period of time may be measured after a diagnosis that the subject is at risk for calpain-mediated physiological damage, or after a particular ischemic event, such as a cardiovascular ischemic event. The duration of treatment may be, for example, less than about a month, two weeks, one week, or even less than about 72 hours. For example, a patient suffering a stroke can be provided a therapeutically effective dose of an HIV protease inhibitor for about 72 hours or less. Alternatively, the therapeutically effective dosage may be provided for a period of time from about 6 to about 72 hours. However, the duration of therapy with the calpain inhibitors disclosed herein can also be prolonged, for example, in the treatment of chronic angina or recurrent transient ischemic attacks (TIA's). Moreover, administration can be repeated, but intermittent (for example, following an episode of angina or TIA), even though intermittent or episodic administration would be avoided in an antiviral treatment because it could lead to the development of viral drug resistance.
- The specific dose level, frequency of dosage, and duration of treatment for any particular subject may be varied and will depend upon a variety of factors, including: the activity of the specific pharmaceutical composition; the metabolic stability and length of action of that composition; the age, body weight, general health, gender, diet, and other characteristics of the subject; mode and time of administration; the rate of excretion; drug combination parameters; and severity of the condition of the subject undergoing treatment.
- The pharmaceutical compositions can be used in the treatment of a variety of conditions or diseases associated with calpain activation, including conditions or diseases caused by or mediated by enzymatically active calpains. Examples of conditions or diseases associated with calpain-mediated physiological damage include, but are not limited to, neurological conditions such as cerebral trauma, spinal cord trauma, subarachnoid hemmorrhage, Alzheimer's disease, alcohol-induced brain damage, muscular dystrophy; as well as non-neurological conditions, such as cataract, coronary atherosclerosis, restenosis, and arthritis. Post-ischemic calpain activation also may be associated with a cardiovascular ischemic event such as, for example, myocardial infarction, angina, cardiac trauma, arhythmia, stroke, thrombosis, or thrombotic platelet aggregation. The trauma or condition leading to the calpain-mediated physiological damage may be induced or accidental.
- While the present invention is described in connection with at least one preferred embodiment, the scope of the present invention is not intended to be limited to any particular embodiment. Instead, the descriptions and examples disclosed are intended to cover all alternatives, modifications, and equivalents that may be included within the spirit and scope of the invention as defined by the claims.
- The following examples are provided to illustrate particular features of various described embodiments. The scope of the present invention should not be limited to those features exemplified.
- Using standard experimental methods, ritonavir was unexpectedly found to competitively inhibit calpain with an inhibition constant of about 11 μM.
- PC12 cells were grown in an RPMI solution containing 5% fetal bovine serum, 10% heat-inactivated horse serum, and 50 mg/L gentamicin. Cells were isolated by centrifugation, and cell pellets suspended in 1 mL of extract buffer, containing 30 mM TRIS at pH 6.8, 15 mMEDTA, 5 mMEGTA, 1 mMDTT, 0.5 M PMSF, 0.1 mg/mL AEBSF, 14.4 mM 2-mercaptoethanol, and 1% triton x-100. After 1 cycle of freeze-thaw, the cell extract was centrifuged at 4° C. at 14,000 g for 20 minutes. The supernatant was removed and assayed.
- Calpain activity was measuring using N-succinyl-leu-tyr 7-amino-4-methylcoumarin as the specific peptide substrate. Fluorescence was measured in a 96-well microplate format (Dyrex Technologies (UK), Middlesex) with a 380 nm excitation filter and 480 nm emission filter. Total volume for each well was 300 μL containing Hanks' Balanced Salt Solution 1×(Cellgro), 2 μM calcium chloride, and varying amounts of inhibitor and N-succinyl-ley-tyr-7-amino-4-methylcoumarin.
- Data consisting of relative fluorescence units (RFU) was obtained every two minutes for 1 hour. Data was analyzed based on initial rate, defined as the slope of the increase of the obtained RFU value up to a maximum length of 10 minutes. Data from seven separate experiments performed was used for the analysis. Each experimental point resulted from the mean of the six estimates. Within each experiment, maximal rate of the μ-calpain and m-calpain isoforms was obtained in the presence of 8 mM calcium. Four different substrate concentrations (0 μM, 1 μM, 10 μM, 100 μM) were tested.
- Steady-state kinetic data were fit to a series of equations describing competitive, noncompetitive, and uncompetitive inhibition using non-linear regression, for example the NLREG computer software program, which is available from SoftSeek.com and performs function error minimization using a Newton-Gauss algorithm. Model sufficiency was evaluated based on whether the objective function converged with a tolerance factor of 1×10−10, the overall F-value for the regression, and the magnitude and sign of the parameters obtained after convergence.
-
- where vi is the velocity in the presence of inhibitor, and vm is the velocity in absence of inhibitor.
-
- where
-
- E=concentration of enzyme
- I=concentration of inhibitor
- A=substrate concentration
- Ka=Michaelis-Menten constant
-
-
-
-
- where Ki in Formula (6) is the dissociation constant for the enzyme-substrate-inhibitor complex.
-
- where Kia is the dissociation constant of the enzyme-substrate complex and Kii is the dissociation constant of the enzyme-substrate-inhibitor complex.
- Calpain specific activity was obtained by subtracting the rate obtained in the presence of calcium from the rated obtained in the absence of calcium. In these cell extracts, the observed kinetic parameters represent aggregate estimates since both calpain isoforms were present.
- The best model fit was found to occur with the competitive inhibitor model, having an overall F-value of 118.48 with an associated p≦0.00001. The observed Ki for ritonavir was (mean±standard error of the mean) 11.0±7.0 μM. The observed Ka was 0.4±0.3 mM. The two other possible models for inhibition—noncompetitive and uncompetitive inhibition—were rejected as the parameters failed to converge, or converged to negative values.
- The inhibition constant for ritonavir was measured in whole PC12 cells in a manner similar to that described in Example #1. Whole cell enzymatic activity was measured as previously described in DePetrillo, Neurochem. 68:1863-69 (1997). The same four inhibitor concentrations were tested, but the substrate concentration was held at 80 μM. As in Example #1, calpain specific activity was obtained by subtracting the rate obtained in the presence of calcium from the rated obtained in the absence of calcium.
- When calpain inhibition by ritonavir was examined in whole PC12 cells with a calcium concentration of 1.4 mM in the presence of 10 μM ionomycin, competitive inhibition was found, with Ki=3.0 μM (i.e., for m-calpain activation). At calcium concentrations of 0.14 mM, Ki=7.7 μM (i.e., for μ-calpain activation).
- Using standard experimental methods, ritonavir was unexpectedly found to increase survival of hippocampal primary neurons exposed to 4-hydroxynonenal (HNE) induced oxidative stress.
- Hippocampal primary neuron cell cultures were prepared according to the methods described by Mattson, et al., Methods Cell Biol., 46:187-216 (1995). Hippocampi were obtained from rat embryos and incubated for 15 minutes in a solution of 2 mg/ml trypsin in Hank's Balanced Salt Solution (HBSS) containing 2.4 g/l N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid] (HEPES) and 10 mg/l gentamicin, pH 7.2 at a concentration of 2 hippocampi/ml. The hippocampi were then rinsed three times in 10 ml of HBSS and incubated for 5 min. in a solution of 1 mg trypsin inhibitor/ml of HBSS. Finally, the cells were rinsed three times with 10 ml of HBSS.
- Cells were dissociated by trituration through the narrowed bore of a fire-polished Pasteur pipette and distributed to 35 mm polyethylenimine-coated plastic culture dishes containing 1 ml of MEM+. MEM+consisted of Minimum Essential Medium (MEM) supplemented with 10% heat inactivated-fetal bovine serum, 10 mM sodium bicarbonate, 20 mM KCl, 1 mM pyruvate, 0.5 mM glutamine, 10 g/l glucose, and 10 mg/l gentamicin at pH 7.2. After a 4 hour incubation at 37° C. in humidified 6% CO2/94% room air, MEM+ was replaced with B-27-supplemented Neurobasal medium. Cultures were maintained in this medium for 7 days until this analysis was performed.
- The effect of ritonavir on hippocampal neuronal survival against HNE toxicity was evaluated in primary cultures when the cultures were 8 days old. Ritonavir was prepared in dimethysulfoxide (DMSO) at a stock concentration of 10 mM. HNE was freshly prepared in Locke's solution at the stock concentration of 1 mM. The Locke's solution consisted of 154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 1.0 mM MgCl2, 3.6 mM NaHCO3, 5 mM glucose, 5 mM HEPES, 0.01 mg/ml phenol red, at pH 7.2.
- Ritonavir was assayed at the following concentrations: 1 pM, 10 pM, 100 pM, 1 nM, and 10 nM in Locke's solution. The final concentration of HNE was 1 mM. The effect of ritonavir alone on hippocampal neuron survival was examined at the each of the above concentrations. The cytoprotective effect of ritonavir also was evaluated in combination with 1 mM HNE. For the combination of ritonavir and HNE, the culture was pre-treated with ritonavir at least 15 min. prior to adding HNE solution. The control cultures without ritonavir or HNE were treated with Locke's solution containing 10 nM of DMSO to match the DMSO content in ritonavir-treated cultures. Four dishes were examined for each of the groups.
- Each of the cultures was photographed with phase-contrast inverted Zeiss microscope attached with a 35 mm camera at pre-treatment, 24 hours, and 48 hours after treatment at the same location marked by a scratched grid on the bottom of culture dish. Two photos were taken from each of the dishes. Neuronal survival was quantified by counting the number of neurons on each of the photos. Neuronal viability was identified and determined by morphological criteria: viable neurons had phase-bright somas and intact processes while nonviable neurons had phase-dark, vacuolated somas, and fragmented neuritis. The survival rate was calculated for each of the dishes by using the number of surviving neurons at the 24 hour or 48 hour time point divided by the number of surviving neurons at pre-treatment from the same dish.
- Hippocampal primary neurons maintained in Locke's solution (Control Group) showed a slight time-dependent decrease in survival. Treatment with either HNE, ritonavir, or combination of both significantly affected cell survival in hippocampal primary neurons in a time-dependent manner (Treatment, F11,36=5.46, p<0.001; Time, F1,36=294.48, p<0.001).
- Exposure of the cell cultures to HNE at the concentration of 1 μM limited neuronal survival. After either a 24 hour or 48 hour exposure period, neuronal survival significantly decreased in HNE-treated culture (p<0.05 as compared to control, ritonavir 1 pM, ritonavir 10 pM, ritonavir 100 pM, and ritonavir 100 pM+HNE).
- Ritonavir alone in culture medium induced concentration-dependent effects on neuronal survival. At lower concentrations of 1-100 pM, ritonavir itself had no effect on cell survival as compared to control cells. At higher concentrations of 1 nM, and particularly 10 nM, ritonavir significantly reduced neuronal survival (p<0.05 as compared to control, ritonavir 1 pM, ritonavir 10 pM, ritonavir 100 pM, and ritonavir 100 pM+HNE).
- However, ritonavir was strongly cytoprotective in HNE-treated hippocampal primary neurons. The cytoprotection was dose-dependent, as ritonavir at low concentrations of 1 pM exhibited no cytoprotective activity against HNE-induced cytotoxicity. However, at the concentrations of 10 pM, cytoprotective activity emerged, which increased up to concentrations of 100 pM, where the drug significantly protected hippocampal primary neurons against HNE-induced cytotoxicity (p<0.05 as compared to HNE, ritonavir 1 pM+HNE, and ritonavir 10 pM+HNE). The level of cytoprotection was 100% at this dose level—there was no difference between the ritonavir 100 pM+HNE and the control group in cell survival measures.
- At doses higher than 100 pM, ritonavir exhibited cytotoxicity, since neuronal survival in both ritonavir 1 nM+HNE and ritonavir 10 nM+HNE was significantly lower than in the control, ritonavir 100 pM+HNE, and ritonavir 1-100 pM groups (p<0.05). Exposure to 10 μM ritonavir resulted in essentially 100% cell death after 24 hours.
- Spectrin is a specific substrate of calpains and spectrin breakdown has been shown to be associated with neuronal injury, such as after trauma or NMDA-induced neuronal cell injury. In this example, spectrin was used to assay calpain activity in the presence of ritonavir.
- To maximally activate both μ-calpain and m-calpain, PC12 cells were exposed to 2 mM Ca2+ for fifteen minutes in the presence of 10 μM ionomycin. A western blot of the cell extracts was probed with anti-spectrin antibodies (commercially available from Chemicon International, Inc., of Temecula, Calif.). Undigested spectrin appeared as a band at approximately 240 kD. The spectrin breakdown products appeared at approximately 150 kD, and followed a ladder pattern associated with limited and specific proteolysis.
- Ritonavir at a concentration of 0.1 μM was shown to inhibit spectrin breakdown, demonstrating its ability to inhibit calpain-mediated spectrin breakdown.
- This example illustrates how compounds disclosed herein may be screened for therapeutic effectiveness. In this particular example, ritonavir is used to treat neuronal damage in rats following induced strokes.
- Sixteen adult male and non-pregnant female Sprague-Dawley rats, weighing approximately 300 g each, are divided into four groups of four rats. Group I receives no treatment. Group II is cannulated to induce a stroke, as described below, and orally administered ritonavir. Group III is cannulated, but receives no drug treatment, and Group IV is not cannulated, but is administered ritonavir.
- The number of animals provides an error alpha of 0.05 and a beta (power) of 0.80 with an expected treatment effect size of approximately 1.00. The largest difference in the mean area of brain injury is found between the two treatments incorporating surgery and, expressed in standard deviation units, is equal to [mean1−mean2]/(standard deviation units)≧1.00 (calculations performed according to Cohen,Statistical Power Analysis for the Behavioral Sciences, 2nd edition (Lawrence Erlbaum Assoc. 1988)).
- Drug doses are determined according to the expected blood level of ritonavir after oral administration and the ritonavir Ki. To minimize Type II error rates, ritonavir is administered at a higher normalized dose compared to human dosage recommendations.
- Duration of drug dosing is determined according to a similar rationale. Ritonavir is administered for about 24 hours longer than previously reported calpain inhibitors, to minimize the possibility of a Type II error. The frequency of drug administration will be every 8 hours for similar reasons.
- Ritonavir (15 mg/kg) is orally administered to the rats two hours before the surgical procedure begins, and 10% chloral hydrate (300 mg/kg) is used for anesthesia. The carotid arteries (including the common, external, and internal artery) are surgically exposed, and a siliconized nylon thread is inserted via needle catheter through the external artery into the middle cerebral artery to occlude blood flow in this artery. The thread is left in place for 60 minutes, then withdrawn and the skin sutured.
- An artery occlusion time of 60 minutes initiates reproducible brain tissue injury and mimics stroke injury, where reperfusion can sometimes occur spontaneously or by interventional procedures within an hour.
- Drug administration continues every 8 hours for three days, for a total of 9 doses. Prior to the last dose, a blood sample of 0.5 mL is obtained from the tail vein of each rat and analyzed for drug concentration.
- Seven days after the procedure, all animals are administered a lethal dose of phenobarbital (20 mg/kg), and transcardial perfusion with 120 mL of 0.9% saline and 200 mL 10% buffered formalin. Brains are removed, cut at 2-3 mm, embedded in paraffin, cut into 4-5 μm thick sections, and stained with hematoxylin/eosin and Kluver-Barrera.
- The tissue samples are analyzed for differences in brain injury among the four treatment groups.
- Other examples of calpain inhibitors to be tested in accordance with the assays of Examples 1-3 include, but are not limited to, compounds disclosed in U.S. Pat. Nos. 5,541,206 and 5,413,999, such as the following:
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3-(S)-N′-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl(4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)-yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8aS )-decahydroisoquinoline)yl)-pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-(2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N′(t-butylcarboxamido)-piperazinyl))-pentaneamide, alternatively named [1S-[1α[αS*,γR* ,δ(R*)],2α]]-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-2-[[(1,1-dimethylethyl) amino]carbonyl]-γ-hydroxy-α-(phenylmethyl)-4-(3-pyridinylmethyl)-1-piperazinepentaneamide, or N-(1(S)-2,3-dihydro-2(R)-hydroxy-1H-indenyl)-4)S)-hydroxy-2-(R)-phenyl-methyl-5-[4-(3-pyridylmethyl)-2(S)-t-butylcarbamoyl)piperazinyl]pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N′-(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-1-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl )-2(R)-phenylmethyl-4-(S)-amino-5-(2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8a S)-decahydroisoquinoline)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-phenylpropionyl)-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-benzoyl-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-phenylpropyl)-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-amino-5-(1-(4-carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N′-(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-1-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-amino-5-(2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-(3-phenylpropionyl)-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-benzoyl-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-(3-phenylpropyl)-2(S)-N′-(t-burylcarboxamido))-piperazinyl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-amino-5-(1-(4carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)piperazinyl)pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N′-(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N′-t-butyl4(S)-1-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)ethoxy)phenyl)methyl)-4(S)-amino-5- (2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)-yl)pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-(3-phenylpropionyl)-2(S)-N′-(t-butylcarboxamido)-piperazinyl))pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-benzoyl2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-(3-phenylpropyl)-2(S)-N′-(t-butylcarboxamido))-piperazinyl)-pentaneamide;
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-amino-5-(1-(4-carbobenzyloxy-2(S)-N′-(t-butylcarboxamido)-piperazinyl)) -pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N′-(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N′-t-butyl-4(S)-1-naphthyloxy-prolineamid)yl)-pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-amino-5-(2-(3(S)-N′-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-phenylpropionyl)-2(S)-N′-(t-butylcarboxamido)-piperazinyl))pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-benzoyl-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-phenylpropyl)-2(S)-N′-(t-butylcarboxamido))-piperazinyl)pentaneamide, or (4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-amino-5-(1-(4-carbobenzyloxy-2-(S)N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- (2S,3R,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-((N-Methyl-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino)-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S, 3R,4S,5S)-2-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbon yl)valinyl)amino)-5-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-5-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-5-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-5-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4S,5S)-2-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-5-(N-((5-isothiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N -((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4 R,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3R,4R,5S)-5-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino) -3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino) -3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,4S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclopentyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclohexyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1,1-dimethyl)ethyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl) methoxycarbonyl)amino)1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-cyclobutyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-cyclopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-cyclopentenyl)-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(1-cyclohexenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((4-cyclopentenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((4-cyclohexenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(3-propenyl)-4-thiazolyl)methyl) amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-methyl-1-propenyl)-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-methyl-1-propenyl)-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1,2-dimethyl-1-propenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(cyclopentyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(cyclohexyl)methyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-phenyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-benzyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-phenyl)ethyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-phenyl-1-ethenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5- (N-((N-Methyl-N-((2-(4-fluoro)phenyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-chloro)phenyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(3-methoxy)phenyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(2-thiazolyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S ,5S)-5-(N-((N-Methyl-N-((2-(2-thiazolyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-methoxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-ethoxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyloxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(N,N-dimethylamino)methyl-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-pyrrolidinyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-propyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-methyl)propyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-methyl)propyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-ethyl)propyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclopentyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclohexyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1,1-dimethyl)ethyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino) 1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclobutyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethenyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S ,5S)-5-(N-(N-((N-Methyl-N-((2-(2-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-cyclopentenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(1-cyclohexenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((4-cyclopentenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((4-cyclohexenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(3-propenyl)-4-thiazolyl) methyl) amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-methyl-1-propenyl)-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-methyl-1-propenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1,2-dimethyl-1-propenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(cyclopentyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(cyclohexyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-phenyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-benzyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-phenyl)ethyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-N-((N-Methyl-N-((2-(2-phenyl-1-ethenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(4-fluoro)phenyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-chloro)phenyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(3-methoxy)phenyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(2-thiazolyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-methoxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethoxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyloxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(N,N-dimethylamino)methyl-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-pyrrolidinyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-propyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-methyl)propyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-methyl)propyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-N-((N-Methyl-N-((2-(1-ethyl)propyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclopentyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclohexyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1,1-dimethyl)ethyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclobutyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-cyclopropyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-cyclopentenyl)-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-cyclohexenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((4-cyclopentenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((4-cyclohexenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(3-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S ,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-propenyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-methyl-1-propenyl)-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-methyl-1-propenyl)-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1,2-dimethyl-1-propenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(cyclopentyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(cyclohexyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-phenyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-benzyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(2-phenyl)ethyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-phenyl-1-ethenyl)-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(4-fluoro)phenyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-chloro)phenyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(3-methoxy)phenyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)methyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-methoxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-ethoxy-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyloxy-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(N,N-dimethylamino)methyl-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-(1-pyrrolidinyl)methyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-propyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-methyl)propyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-methyl)propyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-ethyl)propyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Ethyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino) -5-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino) -2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(N,N-Dimethylamino)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino) -1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(N,N-Dimethylamino)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-oxazolyl)methoxycarbonyl)amino) -1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)-methoxycarbonyl)valinyl)amino) -5-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino) -1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-oxazolyl)methoxycarbonyl)amino) -1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((3-Isopropyl-5-isoxazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Ethyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino) -5-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino) -2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(N,N-Dimethylamino)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(N,N-Dimethylamino)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino) -5-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((3-Isopropyl-5-isoxazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-isoxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)alaninyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((N-Ethyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)valinyl)amino) -5-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-Isopropyl-4-thiazolyl)methoxycarbonyl)alaninyl)amino) -2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(N,N-Dimethylamino)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(N,N-Dimethylamino)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-2-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl)amino)-5-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-(N-((3-Isopropyl-5-isoxazolyl)methoxycarbonyl)valinyl)amino) -2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;
- (2S,3S,5S)-5-(N-((N-Methyl-N-((2-isopropyl-4-oxazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-isothiazolyl)methoxycarbonyl)amino)-1,6-dipheny 1-3-hydroxyhexane.
- Although a variety of conditions can be treated using a variety of drug regimens as described herein, the following examples provide some specific instances (without limitation) about treatment of some of these conditions.
- For the treatment of angina or a transient ischemic attack, 300-600 mg of ritonavir are administered twice a day beginning the day of an attack, continued for 72 hours, and then stopped until the next attack occurs.
- In the treatment of more severe ischemia, such as that caused by a myocardial infarction (MI), the same or a lesser dose may be administered for a longer period of time. For example, a compound disclosed herein is administered following initial clinical presentation with signs and symptoms of an MI (such as chest pain and EKG changes), or following laboratory confirmation of the MI (such as presence of elevated cardiac enzyme levels such as CPK-MB). Administration would be continued for at least a week, for example, a month, or in some examples, no more than one or two weeks. Repeated courses of the calpain inhibitor can be given for subsequent MI's or other calpain mediated conditions (such as an ischemic or hemorrhagic stroke).
- In yet other conditions, such as the prevention of cataract, treatment may be sustained (for example, 100-300 mg by mouth each day, for example as a single dose) for life, or until extraction of a cataractous crystalline lens.
Claims (48)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/847,872 US6448245B1 (en) | 2000-05-04 | 2001-05-02 | Methods of and compounds for inhibiting calpains |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20237800P | 2000-05-04 | 2000-05-04 | |
US09/847,872 US6448245B1 (en) | 2000-05-04 | 2001-05-02 | Methods of and compounds for inhibiting calpains |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020115665A1 true US20020115665A1 (en) | 2002-08-22 |
US6448245B1 US6448245B1 (en) | 2002-09-10 |
Family
ID=22749625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/847,872 Expired - Fee Related US6448245B1 (en) | 2000-05-04 | 2001-05-02 | Methods of and compounds for inhibiting calpains |
Country Status (3)
Country | Link |
---|---|
US (1) | US6448245B1 (en) |
AU (1) | AU2001259817A1 (en) |
WO (1) | WO2001082919A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127385A1 (en) * | 2002-12-06 | 2006-06-15 | The Trustees Of Boston University | Method for sustaining enos activity |
US20080108617A1 (en) * | 2006-07-07 | 2008-05-08 | Desai Manoj C | Modulators of pharmacokinetic properties of therapeutics |
US20080207620A1 (en) * | 2007-02-23 | 2008-08-28 | Desai Manoj C | Modulators of pharmacokinetic properties of therapeutics |
US20090175820A1 (en) * | 2008-01-04 | 2009-07-09 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
US20090181902A1 (en) * | 2007-07-06 | 2009-07-16 | Gilead Sciences,Inc. | Modulators of pharmacokinetic properties of therapeutics |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2462875A1 (en) * | 2001-10-05 | 2003-04-17 | Elan Pharmaceuticals, Inc. | Allylamides useful in the treatment of alzheimer's disease |
US20050038019A1 (en) * | 2001-10-29 | 2005-02-17 | Beck James P. | Hydroxy substituted amides for the treatment of alzheimer's disease |
US20030138423A1 (en) * | 2001-12-14 | 2003-07-24 | Cedars-Sinai Medical Center | Method of treating inflammation with HIV-1 protease inhibitors and their derivatives |
EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
WO2012018639A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
EP3249054A1 (en) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulations and methods for stabilizing pcr reagents |
US20160135446A1 (en) | 2013-06-13 | 2016-05-19 | Biomatrica, Inc. | Cell stabilization |
EP3154338B1 (en) | 2014-06-10 | 2020-01-29 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
CN104069117A (en) * | 2014-07-03 | 2014-10-01 | 滨州医学院 | Application of amprenavir in preparation of medicine for preventing or treating ischemic cardiovascular and cerebrovascular diseases |
WO2017100212A1 (en) | 2015-12-08 | 2017-06-15 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
DE4215874A1 (en) * | 1992-05-14 | 1993-11-18 | Bayer Ag | Dithiolanylglycine-containing HIV protease inhibitors of the hydroxyethylene isostear type |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
SK1296A3 (en) * | 1995-01-04 | 1996-08-07 | Bayer Ag | Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances |
CA2270546A1 (en) * | 1996-11-08 | 1998-05-22 | Japan Energy Corporation | Aids remedy |
ZA9710071B (en) | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
GB9712253D0 (en) * | 1997-06-13 | 1997-08-13 | Glaxo Group Ltd | Antiviral compound |
-
2001
- 2001-05-02 WO PCT/US2001/040652 patent/WO2001082919A2/en active Application Filing
- 2001-05-02 US US09/847,872 patent/US6448245B1/en not_active Expired - Fee Related
- 2001-05-02 AU AU2001259817A patent/AU2001259817A1/en not_active Abandoned
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127385A1 (en) * | 2002-12-06 | 2006-06-15 | The Trustees Of Boston University | Method for sustaining enos activity |
US8067449B2 (en) | 2006-07-07 | 2011-11-29 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20080108617A1 (en) * | 2006-07-07 | 2008-05-08 | Desai Manoj C | Modulators of pharmacokinetic properties of therapeutics |
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8383655B2 (en) | 2006-07-07 | 2013-02-26 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20090291952A1 (en) * | 2006-07-07 | 2009-11-26 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US7939553B2 (en) | 2006-07-07 | 2011-05-10 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20110212964A1 (en) * | 2006-07-07 | 2011-09-01 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8486942B2 (en) | 2007-02-23 | 2013-07-16 | Gilead Sciencs, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8148374B2 (en) | 2007-02-23 | 2012-04-03 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20080207620A1 (en) * | 2007-02-23 | 2008-08-28 | Desai Manoj C | Modulators of pharmacokinetic properties of therapeutics |
US9891239B2 (en) | 2007-02-23 | 2018-02-13 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8088770B2 (en) | 2007-07-06 | 2012-01-03 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20090181902A1 (en) * | 2007-07-06 | 2009-07-16 | Gilead Sciences,Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20090175820A1 (en) * | 2008-01-04 | 2009-07-09 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
US8759379B2 (en) | 2008-01-04 | 2014-06-24 | Gilead Sciences, Inc. | Inhibitors of cytochrome P450 |
Also Published As
Publication number | Publication date |
---|---|
WO2001082919A3 (en) | 2002-05-10 |
AU2001259817A1 (en) | 2001-11-12 |
WO2001082919B1 (en) | 2002-07-25 |
US6448245B1 (en) | 2002-09-10 |
WO2001082919A2 (en) | 2001-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6448245B1 (en) | Methods of and compounds for inhibiting calpains | |
US10343985B2 (en) | Cryopyrin inhibitors for preventing and treating inflammation | |
US9820978B2 (en) | Treatment of cerebral ischemia | |
ES2441736T3 (en) | Use of ritonavir to improve the pharmacokinetics of drugs metabolized by cytochrome P450 | |
KR102014875B1 (en) | New therapeutic approaches for treating parkinson's disease | |
US20100298394A1 (en) | Antifungal agents as neuroprotectants | |
KR20080081358A (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
US6593362B2 (en) | Non-peptidic cyclophilin binding compounds and their use | |
USH1649H (en) | HIV protease inhibitor combinations | |
EP3472133A1 (en) | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | |
WO2018003829A1 (en) | Autophagy inhibitor | |
EP1751125B1 (en) | Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound. | |
US10603321B2 (en) | Small molecules targeting HIV-1 nef | |
AU2018343239A1 (en) | Dosing regimen of siponimod | |
US20230218563A1 (en) | Methods for treating or preventing chronic kidney disease | |
US6225307B1 (en) | Viral treatment | |
WO2020144753A1 (en) | Prophylactic or therapeutic drug for neurodegenerative diseases | |
EP2578212B1 (en) | Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses | |
US10064843B2 (en) | Bis-amide derivative and use thereof | |
WO2019009359A1 (en) | Pharmaceutical composition for nasal administration | |
AU716760B2 (en) | Aids therapeutic composition | |
JP2007512319A (en) | Compositions and methods for treating cardiovascular disorders and diseases | |
US20210369680A1 (en) | Methods of treating diseases and disorders resulting from beta coronavirus infection | |
Atta et al. | Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease | |
US5869526A (en) | δ-(S-methylisothioureido)-L-norvaline therapeutic for cerebrovascular diseases having nitric oxide synthase inhibiting factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEPETRILLO, PAOLO B.;WAN, WENSHUAI;REEL/FRAME:012055/0239 Effective date: 20010709 |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140910 |